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RESUMO 
 
As fraturas de fragilidade são um problema de saúde publica com especial incidência na 
população idosa, sendo uma causa importante de incapacidade funcional permanente 
e morte precoce. Decorrem devido a um traumatismo de baixa energia e estão 
associadas a uma doença óssea metabólica, a osteoporose. Até há relativamente pouco 
tempo a identificação de pessoas em risco de fratura era feita através da medição da 
densidade óssea e de acordo com limiares de decisão de tratamento definidos pela 
Organização Mundial da Saúde. No entanto, esta medida demonstrou não identificar 
cerca de 40% dos indivíduos que sofrem uma fratura de fragilidade. Outros fatores de 
risco têm que ser considerados que não apenas a avaliação da quantidade de tecido 
mineralizado, nomeadamente, fatores ósseos (dinâmica celular, estrutura tecidular 
nano e microscópica, etc) e não ósseos (risco de quedas, impacto da queda, massa 
muscular, etc). Os fatores de risco clínico (FRC) (idade, sexo, índice massa corporal, 
doenças crónicas, álcool, tabaco) englobam vários fatores ósseos e não ósseos e são 
preditores independentes de fraturas. Foram criados algoritmos que utilizam FRC e que 
demonstraram ser tão bons ou melhores preditores do risco de fratura do que a 
avaliação da densidade mineral óssea, contudo ainda há um longo caminho a percorrer 
até encontrar a melhor ferramenta para identificar pessoas em risco.   
Nesta tese de doutoramento tivemos por objetivos determinar a prevalência e impacto 
da osteoporose e das fraturas de fragilidade em Portugal e melhorar a estratificação de 
pessoas em risco de fratura através da identificação de novos biomarcadores. Para 
atingir este último objetivo, olhámos para o ambiente celular (em particular para os 
osteoblastos, células formadoras de osso) e para o tecido ósseo (nomeadamente para 
as propriedades mecânicas do osso) e procurámos identificar as suas disfunções em 
doentes com fraturas de fragilidade da anca. A nossa hipótese era a de que fragilidade 
mecânica do osso no idoso está associada a uma desregulação da mineralização óssea 
devido a uma perturbação na diferenciação terminal dos osteoblastos que por sua vez 
se associa a uma anormal expressão dos reguladores da via de sinalização WNT 
[dickkopf-related protein (DKK)1 e DKK2, sclerostin (SOST) e secreted frizzled related 
protein-1 (sFRP-1)]. Colocámos ainda a hipótese de que os níveis séricos dos reguladores 
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da via de sinalização WNT poderiam ser marcadores de fraturas de fragilidade em 
idosos. Por fim, tínhamos por objetivo, melhorar a prática clínica na avaliação do risco 
de fratura e na identificação de indivíduos que devem ser tratados para a osteoporose 
através da realização de consensos clínicos nacionais.  
Este doutoramento cruzou duas áreas distintas da investigação clínica, a epidemiologia 
e a investigação clínica aplicada, por isso, utilizámos duas amostras distintas de 
participantes/ doentes. Para analisar as associações entre os fatores de risco clínico, 
marcadores de diferenciação dos osteoblastos com as propriedades biomecânicas do 
osso e com fraturas, utilizámos uma amostra de conveniência, composta por osso e 
informação clínica dos doentes submetidos a artroplastia total da anca devido a fratura 
de fragilidade e a coxartrose durante 2008 a 2012 no Serviço de Ortopedia do Hospital 
de Santa Maria, Centro Hospitalar Lisboa Norte. A outra amostra é constituída por 
adultos residentes em Portugal avaliados num estudo epidemiológico sobre doenças 
reumáticas, o EpiReumaPt (2011-2013) que deu origem à coorte “Epidemiology of 
Chronic Diseases” (EpiDoC cohort) já com duas avaliações prospetivas (2011-2016). Na 
amostra do EpiReumaPt determinámos a prevalência e impacto da osteoporose em 
Portugal. Para além disso avaliámos especificamente as mulheres acima dos 65 anos de 
idade e determinámos a prevalência, fatores de risco e impacto das fraturas de 
fragilidade neste grupo vulnerável. Os dados da coorte EpiDoC foram utilizados para 
analisar a associação entre os níveis séricos dos reguladores da via de sinalização WNT 
(via reguladora da diferenciação terminal dos osteoblastos) com fraturas de fragilidade. 
Para a realização dos consensos clínicos, necessários na mudança de conceito de 
identificação de indivíduos em risco de fratura, procedemos a uma revisão da literatura 
e colaborámos na realização de recomendações nacionais de osteoporose. 
De seguida, apresentamos os nossos principais resultados. O primeiro estudo desta tese 
de doutoramento, utilizou a amostra do EpiReumaPt e demonstrou que 10,2% dos 
adultos portugueses sofrem de osteoporose, sendo esta prevalência superior nas 
mulheres (17%) do que nos homens (2,6%) e aumenta significativamente com a idade. 
Cerca de 40% dos adultos portugueses com idade igual ou superior a 75 anos têm 
osteoporose. O diagnóstico de osteoporose mostrou estar associado a incapacidade 
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funcional (avaliada pelo Health Assessment Questionnaire) mas não se associou a 
sintomas de ansiedade e depressão. O segundo estudo, analisou as mulheres acima dos 
65 anos do EpiReumaPt e verificou que a prevalência de fraturas de fragilidade neste 
grupo etário é de 20,7%. Contudo, apenas 13,9% das mulheres que referiram história de 
fratura de fragilidade reportaram ter algum dia efetuado terapêutica para osteoporose. 
Os locais de fratura mais frequentes foram: perna, punho, úmero, costelas e cotovelo. 
Os fatores de risco clínico que se mostraram estar associados à existência de fraturas de 
fragilidade foram o aumento de idade, obesidade e diminuição da densidade óssea do 
punho.  
O terceiro trabalho desta dissertação de doutoramento, é de investigação clínica 
aplicada, utilizando a amostra de doentes submetidos a artroplastia total da anca 
(n=92). Neste trabalho testámos as diferentes propriedades mecânicas do osso 
trabecular da anca ex-vivo (rigidez, resistência e ductilidade) e a única propriedade 
mecânica que demonstrou ser significativamente diferente entre as pessoas com fratura 
de fragilidade (n=40) das com artrose (n=52) foi a baixa rigidez óssea (propriedade 
mecânica associada à mineralização). Os fatores de risco associados à baixa rigidez óssea 
nos doentes com fraturas foram o tabagismo e o sexo feminino. No quarto estudo, 
avaliámos 64 doentes submetidos a artroplastia total da anca, 25 por fratura de 
fragilidade e 39 por osteoartrose. Neste estudo, verificámos que no osso femoral, a 
expressão génica de osteocalcina (OC) e o rácio de OC/COL1A (marcador da expressão 
terminal de OB) estão diminuídos no grupo que sofreu uma fratura, quando comparado 
com o grupo de coxartrose. A reforçar este achado, a análise imunohistoquímica do osso 
de um subgrupo de doentes com fratura, demonstrou que os osteoblastos tinham 
menos marcação para OC do que no subgrupo de osteoartrose. Verificámos ainda que 
a baixa expressão génica de OC e o rácio OC/COL1A se associam a menor rigidez, 
resistência e ductilidade do osso trabecular dos doentes com fratura.  
Após estes achados que reforçam a importância da perturbação da diferenciação 
terminal dos osteoblastos nos doentes com fraturas e sabendo que a via de regulação 
principal desta fase é a via WNT, considerámos relevante testar os níveis séricos dos 
reguladores da via WNT (DKK1, DKK2, SOST, WIF-1 e sFRP-1) enquanto marcadores de 
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risco de fratura em mulheres acima dos 65 anos, usando a coorte EpiDoC. Estas 
mulheres foram seguidas durante 2,3±1,0 anos e durante este período ocorreram 62 
fraturas de baixo-impacto. Os baixos níveis séricos de DKK2 associaram-se a um 
aumento de risco de fraturas de baixo impacto independentemente da densidade óssea 
e dos fatores de risco clínico [HR (95% CI) 0,53 (0,32; 0,88)]. Por cada redução de 1 desvio 
padrão dos níveis de DKK2, o risco de fratura aumenta 1,5 vezes. Os outros reguladores 
da via WNT não demonstraram estar associados ao risco de fratura, no entanto o tempo 
de seguimento desta população é pequeno e o número de fraturas também. No futuro 
será necessário testar estes resultados noutras populações.  
No final deste doutoramento, considerámos relevante incentivar a mudança de 
paradigma na identificação de indivíduos em risco para fratura de fragilidade na prática 
clínica em Portugal, até agora muito centrada na avaliação da densidade óssea, para a 
avaliação do risco de fratura individual calculada por um algoritmo (o FRAX) validado 
mundialmente e nacionalmente. Este algoritmo utiliza FRC com ou sem densidade óssea 
para a identificação de pessoas em risco e o limiar de tratamento foi estabelecido com 
base em estudos de custo-efetividade. Sendo esta a melhor ferramenta disponível em 
Portugal para a identificação de pessoas em risco, considerámos relevante implementar 
esta ferramenta na prática clínica através da inclusão da mesma nas recomendações 
clínicas da área da osteoporose.  
Em conclusão, esta tese de doutoramento contribuiu para aumentar o conhecimento 
sobre a prevalência, fatores de risco, taxas de tratamento e impacto da osteoporose e 
das fraturas de fragilidade em Portugal, reforçando a sua importância em termos de 
saúde pública em particular na população idosa portuguesa.  
Do ponto de vista mecanístico, contribuímos para o reconhecimento de que a 
fragilidade óssea do idoso se associa a uma perturbação da formação óssea devido a 
uma desregulação da diferenciação terminal do osteoblasto. Identificámos também que 
os níveis séricos de um dos reguladores da diferenciação terminal do osteoblasto (DKK2) 
se associam ao aumento do risco de fraturas de fragilidade em mulheres acima dos 65 
anos, podendo ser mais uma ferramenta para melhor identificar pessoas em risco de 
fratura. Por fim, colaborámos na elaboração de consensos nacionais baseados na 
RESUMO 
 
 
- 27 - 
melhor evidência científica atual de modo a modificar a prática clínica e a reduzir a 
incidência de novas fraturas de fragilidade em Portugal.  
 
Palavras Chave: Osteoporose, fraturas de fragilidade, Epidemiologia, risco de fratura, 
Via de sinalização WNT 
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ABSTRACT 
 
In this PhD thesis, we aimed to determine the prevalence and burden of osteoporosis 
and fragility fractures in Portugal to provide evidence in support of new health strategies 
to improve clinical care and reduce or prevent disability and mortality among elderly. 
We also aimed to better identify senior women at high risk for a fragility fracture 
through the use of novel noninvasive biomarkers. To achieve this goal, we evaluated 
cellular (osteoblast) and tissue (bone mechanical properties) mechanism dysfunction to 
identify potential serum markers of bone fragility. We hypothesized that bone fragility 
in the elderly is associated with dysregulation of mineralization because of osteoblast 
terminal differentiation and disturbances in Wnt regulators [dickkopf-related protein 
(DKK)1 and DKK2, sclerostin (SOST) and secreted frizzled related protein-1 (sFRP-1)]. 
Moreover, we hypothesized that serum levels of Wnt regulators are associated with 
bone fragility and fractures and can constitute new markers for osteoporosis treatment 
decision. Finally, to create awareness and reduce new fragility fractures in Portugal, we 
aimed to develop national clinical consensus recommendations for osteoporosis 
diagnosis and treatment. 
The studies presented in this thesis crossed two main areas of clinical research, patient-
oriented mechanistic research, and epidemiological research. We used two samples of 
participants/patients. One sample was composed of patients undergoing hip 
replacement surgery (for osteoarthritis or a fragility fracture) in the Orthopaedic 
Department of Hospital de Santa Maria, Centro Hospitalar Lisboa Norte from 2008 to 
2012. It was used to analyse clinical determinants of bone fragility and fractures in the 
elderly, particularly the associations between osteoblast dysfunction, bone mechanical 
properties, and fragility fractures. The other sample was a population based on a 
nationwide sample evaluated in the EpiReumaPt (2011-2013) study. Using the 
EpiReumaPt sample, we determined the prevalence and individual burden of 
osteoporosis in Portugal. Moreover, we analysed the prevalence, burden, and risk 
factors of fragility fractures in a particularly vulnerable stratum, senior women. The 
EpiReumaPt population was then followed in two more waves of evaluation (2011-2016) 
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under the scope of the Epidemiology of Chronic Diseases (EpiDoC) cohort. Using data 
from the EpiDoC cohort, we analysed the association between serum markers of Wnt 
inhibitors (osteoblast regulators) and fragility fractures. Finally, a review of the literature 
was performed to develop national clinical recommendations regarding fracture risk 
assessment and osteoporosis treatment. 
In the first study of this thesis, using the EpiReumaPt sample, we found that 10.2% of 
Portuguese adults have osteoporosis. The prevalence is higher in women (17.0%) than 
in men (2.6%) and increases with age. Almost half (40.0%) of Portuguese adults 75 years 
and older have osteoporosis, and an osteoporosis diagnosis was associated with 
substantial physical function impairment but not with anxiety or depression symptoms. 
The second study, also using EpiReumaPt data, showed that self-reported fragility 
fractures were highly prevalent among senior women (20.7%). This high prevalence was 
in stark contrast with the low rate of osteoporosis treatment (13.9%). Non-hip and non-
vertebral fractures (i.e., lower leg, wrist, humerus, rib, clavicle, and elbow fractures) 
accounted for the majority of fragility fractures, and clinical risk factors independently 
associated with prevalent fragility fractures were increased age, obesity, and lower 
distal bone mineral density (BMD). 
The challenge to better identify seniors (people aged ≥65 years old) at high risk for a 
fragility fracture led us to search for novel noninvasive biomarkers of bone fragility and 
fractures. To achieve this goal, we conducted patient-oriented mechanistic research, 
evaluating associations between cellular mechanism dysfunction and bone fragility 
among patients undergoing hip replacement surgery. In the third research work of this 
thesis, we demonstrated that when adjusted for differences in age, sex, and body mass 
index, the only macrostructural bone characteristic that remained significantly different 
between patients with hip fragility fractures and those with osteoarthritis was 
trabecular stiffness (which is linked to mineralization disturbances). Stiffness was lower 
in patients with fragility fractures. We also found that smoking habits and female sex 
were independently associated with lower stiffness in patients with a fragility fracture.  
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In the fourth study of this thesis, we evaluated markers of osteoblast differentiation, as 
these are the cells responsible for the production of mineralized tissue. We found that 
osteocalcin (OCL) relative bone expression and the OCL/type 1 collagen, alpha 1 chain 
(COL1A1) expression ratio in bone (a marker of osteoblast terminal differentiation) were 
significantly lower in patients with hip fractures than in those with osteoarthritis. 
Consistent with these results, in a subset of patients, fewer osteoblasts stained for OCL 
in patients with a fragility fracture than in those with osteoarthritis. We also 
demonstrated that in patients with hip fractures, a low bone OCL/COL1A1 expression 
ratio was associated with worse trabecular mechanical behaviour. This work reinforced 
the importance of osteoblast dysfunction in bone intrinsic properties and fractures 
among the elderly.  
In our fifth study, we examined whether the Wnt inhibitors DKK1, DKK2, SOST, WIF-1, 
and sFRP-1 (regulators of osteoblast differentiation and bone formation) were 
associated with BMD or fragility fractures in a population-based cohort. Using EpiDoC 
cohort data, we found that low serum levels of DKK2 predicted low-impact fractures, 
independent of BMD, and clinical risk factors for fracture. For every 1 standard deviation 
decrease in DKK2, fracture risk increased by approximately 1.5-fold. Serum levels of 
DKK2 were not associated with vertebral or hip BMD. Our results suggest a possible 
interaction among BMD, FRAX score without BMD, and serum DKK2 levels in the 
assessment of fracture risk, which requires further investigation in a larger study with 
longer follow-up. 
The final work of this PhD thesis involved performing a literature review and establishing 
national consensus recommendations regarding fracture risk assessment and 
osteoporosis clinical management and treatment to change clinical practice and reduce 
the incidence of fragility fractures in Portugal. 
In conclusion, this thesis provided rigorous epidemiological data regarding the 
prevalence of osteoporosis and fragility fractures in Portugal. It contributed to refining 
fracture risk assessment through the identification of new serum markers (among 
regulators of osteoblast-mediated bone formation) of bone fragility and fractures. 
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Mechanistic research regarding bone biomechanics and osteoblast dysfunction showed 
that fragility fractures are associated with reduced bone stiffness, reflecting 
mineralization disturbances. Furthermore, reduced osteoblast terminal differentiation 
was associated with poor bone mechanics and fractures. Finally, national consensus 
recommendations were created to improve fracture risk assessment of individuals, as 
well clinical management and treatment of osteoporosis, with the goal of reducing 
fragility fractures in Portugal. 
 
Key words: Osteoporosis, Fragility fractures, Epidemiology, Fracture risk, Wnt signalling 
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THESIS OUTLINE 
 
This thesis describes the foundations and results of 7 years of work dedicated to 
improving fragility fracture prevention, which focused on aspects ranging from the 
assessment of individual patients to driving changes in national health policies. First, we 
aimed to provide rigorous epidemiological data regarding the prevalence of 
osteoporosis and fragility fractures. Then, we conducted rigorous research in a 
nationwide cohort to refine fracture risk assessment through the identification of new 
serum markers of bone fragility and fractures. The rationale for these candidate markers 
(which are regulators of osteoblast-mediated bone formation) originated from studying 
bone biomechanics and osteoblast dysfunction in senior patients with hip fractures. 
Finally, we created national consensus recommendations regarding fracture risk 
assessment, as well as osteoporosis clinical management and treatment, with the goal 
of changing clinical practice and reducing the incidence of fragility fractures in Portugal. 
This thesis is divided into six chapters. In Chapter I (Introduction), we present the 
rationale for conducting this research in light of current knowledge. A general 
introduction to the problems of osteoporosis and fragility fractures is presented, 
including national and international epidemiological data and information regarding 
individual and societal burden and economic impact, focusing on national 
epidemiological unmet needs. We also discuss current knowledge regarding the cellular 
and biomechanical disturbances of osteoporosis and fragility fractures, emphasizing the 
identification of potential markers of bone fragility and fractures. Finally, we address the 
challenges of assessing an individual´s fracture risk and discuss strategies to improve 
fracture risk prediction.  
In Chapter II (Aims), we describe the aims of this thesis. Both the general and specific 
aims are included.  
In Chapter III (Methodology), we briefly describe the methodology used during the 
research. This thesis involves two groups of participants. One group is composed of 
patients undergoing hip replacement surgery (because of osteoarthritis or fragility 
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fractures) between 2008 and 2012 in the Orthopaedic Department of Centro Hospitalar 
Lisboa Norte. The other group is a population-based nationwide sample evaluated by 
survey in the EpiReumaPt study (2011-2013). The EpiReumaPt population was 
subsequently followed in two additional waves of evaluation (2011-2016) under the 
scope of the Epidemiology of Chronic Diseases (EpiDoC) cohort. We include two papers 
in the methodology section. The first is a comprehensive description of the EpiReumaPt 
methodology, which includes data collection, the attrition of participants, and data 
management. The second paper describes the EpiDoC cohort. 
In Chapter IV (Results), we present the results of this thesis in four sections. Section I 
addresses the prevalence and burden of osteoporosis and fragility fractures in Portugal 
and treatment rates for osteoporosis in high-risk patients. It comprises two papers. The 
first (Part 1) estimates the prevalence and burden of osteoporosis among the adult 
Portuguese population. The second (Part 2) estimates the prevalence, burden, and 
undertreatment of osteoporosis among Portuguese senior women (aged ≥65 years old). 
Section II includes a set of studies identifying clinical risk factors and cellular 
disturbances associated with poor trabecular intrinsic mechanical behaviour and hip 
fractures. This section includes two papers. The first (Part 1) analyses clinical risk factors 
associated with bone fragility in patients with hip fractures. The second paper (Part 2) 
analyses the association between osteoblast terminal differentiation and poor bone 
quality, as well as fragility fractures. Section III addresses the hypothesis that serum 
levels of osteoblast terminal differentiation regulators could be surrogate markers of 
bone fragility and fractures. It includes one paper (Part 1) that evaluates serum markers 
of bone remodelling as risk factors of fragility fractures in a nationwide cohort of senior 
women. Section IV describes the development of national clinical consensus 
recommendations regarding individual fracture risk assessment as a strategy to reduce 
the occurrence of new fragility fractures. Part 1 involves multidisciplinary Portuguese 
recommendations regarding indications for dual energy X-ray absorptiometry (DXA) and 
indications for initiating treatment to prevent fragility fractures. Part 2 involves an 
update of the Portuguese recommendations for the prevention, diagnosis, and 
management of primary osteoporosis. 
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Chapter V (General Discussion and Conclusions) comprises an overall discussion of the 
main results of this thesis and possible implications for clinical practice and national 
health policies. The main conclusions and future perspectives are also included in this 
chapter.  
In Chapter VI (References), we list the references cited in this work. 
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CHAPTER I - INTRODUCTION 
 
Definition of Osteoporosis and Fragility Fractures  
 
In 1993, the World Health Organization (WHO) defined osteoporosis as a metabolic 
skeletal disease characterized by low bone mass and microarchitecture deterioration, 
with consequent increased bone fragility and risk of fracture (1). Osteoporosis is one of 
the most common rheumatic and musculoskeletal diseases (RMDs) in the elderly (2). It 
is a multifactorial disease, and several conditions can cause loss of bone mass and 
compromised bone strength. In women after menopause, osteoporosis can occur 
because of a sudden high rate of bone loss resulting from a lack of oestrogen (3). 
Osteoporosis can also be secondary to a disease or treatment, such as 
hyperparathyroidism, hypogonadism, rheumatoid arthritis, malabsorption syndrome, 
or glucocorticoid therapy, that compromises the attainment of peak bone mass during 
skeletal growth or significantly accelerates the loss of bone mass (4).  
Osteoporosis is clinically silent until a fracture occurs. Worldwide, approximately 9 
million fragility fractures are caused by osteoporosis each year, of which more than half 
occur in the American continent and Europe (5, 6). Fragility fractures are defined as any 
fracture resulting from minimal or no trauma, such as those resulting from a fall from 
standing height or less. Fragility fractures are more frequent, and their occurrence 
increases exponentially in senior individuals (people aged ≥65 years old). In fact, before 
the age of 50 years, few fractures are reported (7-9). Although the most commonly 
studied fragility fractures are vertebral and hip fractures, several epidemiological 
studies have shown that the most common fragility fractures are non-hip and non-
vertebral (e.g., wrist, humerus, pelvis, rib, tibia, clavicle) (7-9). Fragility fractures are 
associated with low bone mineral density (BMD) and a higher risk of recurrent fragility 
fractures (3, 10-14). This is true not only for vertebral and hip fractures but also for non-
vertebral non-hip (NVNH) fractures. Recent studies have identified an association 
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between NVNH fractures and a low BMD, higher risk of subsequent fractures, and 
negative health outcomes (7, 8, 13, 14).  
Epidemiology of Osteoporosis, Clinical Risk Factors, and Burden of Fragility Fractures 
The increase in worldwide life expectancy has increased the prevalence of osteoporosis 
and the incidence of fragility fractures (15, 16). In Europe, the estimated prevalence of 
osteoporosis in 2010 was 5.5% of the general population. However, because 
osteoporosis prevalence increases with age and is more common in females, the 
prevalence of osteoporosis among people 50 years and older was 6.6% in men and 
22.1% in women (6). The clinical significance of osteoporosis is a fracture resulting from 
bone fragility. In Europe, an osteoporotic fracture occurs every 30 seconds, and more 
than 3.5 million people suffer a fragility fracture each year (2, 17, 18). The individual 
lifetime risk of a hip, vertebral, or wrist fracture is 30% to 40%, which is similar to the 
risk of a cardiovascular event (19).  
Several epidemiological studies have identified clinical risk factors for fragility fractures, 
such as age (> 65 years), female sex, low body mass index (BMI), prior fragility fracture, 
parental history of hip fracture, long-term use of oral glucocorticoids (> 5 mg 
prednisolone or equivalent for longer than 3 months), current smoking, high intake of 
alcohol (> 3 units/day), rheumatoid arthritis and other secondary causes of osteoporosis 
(e.g., diabetes mellitus, hypogonadism, anorexia nervosa, inflammatory bowel disease, 
calcium/vitamin D deficiency, hyperparathyroidism), prolonged immobilization and 
paralysis, medications (e.g., anticonvulsants, antiretroviral therapy) (20-23), and 
frequent falls (21, 24). These clinical risk factors are integrated in several fracture risk 
prediction tools that are now commonly used worldwide (25).  
Fragility fractures are an important cause of morbidity, mortality, and healthcare costs 
(26-28). In Europe, 37 billion euros per year are spent in healthcare costs related to 
fragility fractures. After sustaining a fragility fracture, individuals experience pain and 
impaired physical function, and some require hospitalization. For the majority, recovery 
is slow, and rehabilitation is often incomplete, leading to permanent disability. In fact, 
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1% of disability-adjusted life years attributable to non-communicable diseases is due to 
fragility fractures (2, 17, 29). 
Differences exist between countries regarding the prevalence of osteoporosis and the 
incidence of fragility fractures. Both osteoporosis and fragility fractures are more 
frequent in northern Europe than in southern Europe (30, 31). In Portugal, 
epidemiological data of fragility fractures are lacking, and only incidence rates of hip 
fractures are well characterized. It has been estimated that 10,000 hip fractures occur 
each year, with regional differences in incidence that must be taken into consideration 
by national healthcare system planners (32-34). Moreover, hip fractures in Portugal are 
responsible for 12% mortality excess and cost 216 million euros per year (34). 
To prevent fractures and increase the quality of care of people sustaining a low-impact 
fracture, more precise data are required regarding the prevalence and burden of 
osteoporosis and fragility fractures in Portugal. In particular, it is important to increase 
the body of knowledge regarding NVNH fractures, which account for the majority of low-
impact fractures (7). This thesis used the EpiReumaPt study, as well as prospective 
follow-up of this population (the EpiDoC study), to fill this knowledge gap. 
 
Bone Biomechanics Disturbances in Osteoporosis and Fracture Risk 
Bone is a highly dynamic, mineralized connective tissue. Its main functions are support 
and protection of soft tissues, attachment of tendons and ligaments for locomotion, 
storage of calcium and phosphate, and harbouring bone marrow. This living tissue is 
light, to allow movement; relatively flexible, to allow deformation and absorb energy 
during impact loads; and relatively stiff, to resist loads and ultimately prevent fractures 
(35). Overall bone strength depends on the homeostasis of bone mechanical properties, 
which are determined by its material composition and hierarchical structure (Figure 1). 
Bone is composed of an organic matrix, composed chiefly of type I collagen (COL1), as 
well as an inorganic phase, composed primarily of calcium hydroxyapatite crystals (36). 
The organic matrix provides flexibility, whereas the mineral content is responsible for 
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stiffness. Variations in tissue mineral density affect function and low BMD is associated 
with reduced bone strength (37). However, bone fragility can also be the result of failed 
material or structural adaptations, not only decreased bone mass. 
 
Figure 1. Hierarchical structure of bone. 
 
To resist a fracture, bone composition in all dimensions is important. This includes the 
amount of bone (bone mass quantity), the spatial distribution of bone mass (e.g., 
trabecular vs cortical bone), and the intrinsic properties of bone material. At the 
nanoscale level, the triple helix of COL1 confers strength in tension, and collagen 
crosslinks keep the helices together. Too few crosslinks can lead to helix separation, 
whereas too many crosslinks diminish the ability to absorb energy (35, 38). At the 
microscopic level, less trabecular interconnectivity or more cortical porosity is related 
to bone fragility. Bone strength also depends on bone size and shape: long bones have 
higher resistance to a compressive load than vertebrae.  
The role of the intrinsic properties of bone material in osteoporosis is emphasized by 
observations that in patients with osteoporosis treated with anti-osteoporotic agents, 
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fracture risk remains unchanged when there are no modifications of bone matrix 
volume or microarchitecture (39-43). Similarly, a 10% increase in areal BMD in women 
receiving anti-resorptive therapy was insufficient to explain the 40% reduction in 
fracture risk (44). Thus, the effect of both anti-resorptive and anabolic therapy in bone 
material properties (namely bone matrix mineralization) must be considered (40, 42, 43, 
45). 
Some recent studies showed that certain clinical risk factors, such as age, sex, race, and 
BMI, influence bone mechanical properties. The bones of elderly individuals have poorer 
mechanical properties than those of younger individuals (46). Men and women differ in 
bone size, and men consequently have a higher bone mineral content (47). There are 
also racial differences in bone strength that are only partially explained by the higher 
bone mineral content (48). However, little is known regarding other clinical risk factors 
for osteoporosis, such as alcohol consumption and smoking. Moreover, the effect size 
of each clinical risk factor on bone intrinsic mechanical properties is unknown. This 
thesis analysed the association between disturbances of bone intrinsic mechanical 
properties and clinical risk factors among the elderly.  
 
Cellular Environment Disturbances in Osteoporosis and Fracture Risk 
Bone is in constant adaptation through cellular mechanisms of bone modelling 
(construction) and remodelling (reconstruction). Bone modelling involves the 
construction of new bone without previous bone resorption; it produces changes in 
bone size and shape. By contrast, bone remodelling is the process of bone resorption 
and formation that occurs daily in the skeleton; it maintains bone strength throughout 
life (35). Bone is remodelled by the action of basic multicellular units (BMUs), which are 
composed of osteoblasts, the cells that form mineralized matrix, and osteoclasts, the 
cells that resorb mineralized matrix. As shown in Figure 2, osteoblast and osteoclast 
functions are coupled. Osteocytes (fully differentiated osteoblasts embedded in the 
mineralized matrix) are pivotal cells in both modelling and remodelling because they 
regulate differentiation and proliferation of both osteoclasts and osteoblasts (49). Bone 
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mass is maintained by a balance between the volume of bone resorbed and the volume 
of bone formed in each BMU, whereby bone resorption and new bone formation are 
temporally and spatially synchronized in a very finely regulated manner. 
Bone modelling occurs mainly during growth and is necessary to achieve peak bone 
mass, which occurs at 18 to 25 years of age. Peak bone mass is mostly (60% to 80%) 
determined by genetic factors, but it is also influenced by sexual hormones and 
environmental factors, such as physical activity and nutrition (e.g., calcium intake) (50). 
Physiologically, bone remodelling is necessary for fracture healing and skeletal 
adaptation to mechanical forces, by removing damaged bone and forming new bone. It 
is also required for calcium homeostasis (Figure 2). During midlife, women have high 
rates of bone remodelling because of oestrogen deficiency, which leads to accelerated 
loss of bone mass and bone fragility. Later in life, both sexes have higher rates of bone 
remodelling and a decline in periosteal bone formation, compared with younger 
individuals, which results in structural deterioration (51).  
 
Figure 2. Bone remodelling. 
 
Bone-resorbing multinucleated osteoclasts are derived from hematopoietic stem cells. 
Osteoclast progenitors differentiate into pre-osteoclasts in response to macrophage 
colony-stimulating factor. In addition, full differentiation and activation of osteoclasts 
depends on the receptor activator of nuclear factor-kB (RANK)–RANK ligand (RANKL)–
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osteoprotegerin (OPG) axis in osteoblasts (Figure 3) (52). Oestrogen deficiency after 
menopause increases bone loss by activating RANKL-induced osteoclast differentiation 
(53). Similarly, the decline of both oestrogen and androgen in older men is associated 
with age-related osteoporosis by increasing osteoclast formation and function through 
this axis (54). In the elderly, osteoclastogenesis is also enhanced by low serum levels of 
vitamin D and calcium, which lead to increased production of parathyroid hormone 
(PTH) (55). In inflammatory diseases, such as rheumatoid arthritis, inflammatory 
cytokines also activate the RANK-RANKL-OPG axis, thereby enhancing 
osteoclastogenesis and bone resorption (56) (Figure 3).  
 
 
Figure 3. Factors influencing osteoclast differentiation and activation. 
(RANK, receptor activator of nuclear factor kappa; RANKL, RANK ligand; OPG, osteoprotegerin; M-CSF, macrophage 
colony-stimulating factor; BMP2, bone morphogenetic protein 2; TGFb, transforming growth factor beta; PGE2, 
prostaglandin E2; PTH, parathyroid hormone; IGF1, insulin-like growth factor 1) 
 
Osteoblasts are mononuclear cells specialized to secrete the collagenous bone matrix 
where hydroxyapatite crystals deposit. They are derived from mesenchymal stem cells 
and require runt-related transcription factor 2 (RUNX2), osterix (OSX), and β-catenin to 
differentiate into osteoblasts (Figure 4) (57, 58). Osteoblasts differentiate and mature 
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from their progenitors in response to several regulatory factors, including bone 
morphogenetic proteins (BMPs), insulin-like growth factor (IGF)-I, fibroblast growth 
factor (FGF)-2, PTH, vitamin D, tumour necrosis factor (TNF), Wnt signalling, and other 
extracellular signals (59-65).  
The Wnt/β-catenin pathway is essential for osteoblast proliferation and differentiation 
(66, 67). Activation of this pathway also reduces osteoblast apoptosis, favouring bone 
formation, mineralization, and increased bone mass (68). Upon binding of a Wnt ligand 
to the receptor frizzled (FZ) and the co-receptors low density lipoprotein receptor-
related proteins (LRPs) 5/6 (67, 69), glycogen synthase kinase (GSK)-3β is inhibited 
through mechanisms involving Axin, Frat-1, and disheveled (Dsh). β-catenin is then 
translocated to the nucleus, where it activates transcription of target genes (67). In the 
absence of a Wnt ligand, cytosolic b-catenin is degraded, and the expression of Wnt-
responsive genes is suppressed (70). The Wnt signalling pathway is regulated by several 
antagonists, such as the secreted frizzled-related protein (sFRP) family and Wnt 
inhibitory factor (WIF)-1 (71, 72). Moreover, Dickkopf-related protein (DKK) 1 [29] and 
sclerostin (SOST) are both potent inhibitors of the Wnt pathway; they reduce LRPs 5/6 
activity and consequently blunt osteoblast differentiation and bone formation (70). The 
Wnt/β-catenin pathway has been widely studied, and its inhibitors are now under 
investigation as new therapeutic targets for osteoporosis (73). In addition, LRP4 has 
recently been identified as a novel DKK1 and SOST receptor, facilitating the inhibition of 
Wnt signalling (74, 75). DKK2 is another molecule of interest since, depending on the 
cellular context, DKK2 inhibits Wnt signalling and stops osteoblast proliferation or acts 
to induce osteoblast maturation. In fact, DKK2-null mice are osteopenic and have 
defects in bone mineralization (76). Thus, the role of DKK2 is to act as a fine-tuning 
regulator of osteoblast maturation and bone mineralization (Figure 4).  
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Figure 4. Regulators of osteoblasts differentiation, proliferation, and maturation. 
 (MSC, mesenchymal stem cells; DLX5, distal-less homeobox 5; RUNX2, runt-related transcription factor 2; OSX, 
osterix; CTNNB1, catenin beta 1; Vit. D, vitamin D3; PTH, parathyroid hormone; IGF1, insulin-like growth factor 1; 
WNT, wingless; SOST, sclerostin; DKK-1, Dickkopf-related protein 1; sFRP, secreted frizzled-related protein; WIF-1, 
Wnt inhibitory factor 1; DKK-2, Dickkopf-related protein 2; LRP5/6, low density lipoprotein receptor-related proteins 
5/6; APC, activated protein C; GSK3, glycogen synthase kinase-3; FZ, frizzled protein; DVL, disheveled; LEF, lymphoid 
enhancer factor; TCF, T-cell factor; b-cat, beta catenin; ALP, alkaline phosphatase; BSP, bone sialoprotein; COL1, 
collagen type I; OPN, osteopontin; OCL, osteocalcin; RANKL, receptor activator of nuclear factor kappa ligand; OPG, 
osteoprotegerin) 
 
Wnt signalling is associated with age-related loss of bone mass. In fact, serum levels of 
DKK1 and SOST increase with ageing and are associated with bone mass loss (77-79). 
Mirza and colleagues found that serum SOST levels were not only significantly higher in 
post-menopausal women, but they were also inversely associated with the free 
oestrogen index (80). In addition, treatment with either anti-SOST or anti-DKK1 
antibodies in animal models of post-menopausal osteoporosis revealed an increase in 
bone formation, bone mass, and bone strength (81, 82). 
One of the consequences of osteoblast dysfunction is impaired synthesis of collagen and 
osteocalcin (OCL) and, consequently, decreased mineralization ability. Differentiated 
osteoblasts synthesize COL1, which acts as a scaffold for deposition of minerals, as well 
as non-collagenous proteins (such OCL) that organize mineral orientation in the collagen 
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scaffold (83, 84). Osteoblast activity can be measured by gene expression of COL1a1 and 
OCL in bones (85). Osteoblasts express COL1a1 at the beginning of their differentiation 
and, thereafter, total collagen synthesis declines as maximal expression of OCL occurs 
when osteoblasts become terminally differentiated (76, 83-86). Therefore, the ratio of 
OCL/COL1a1 expression in bone is an indicator of the proportion of osteoblast terminal 
differentiation and mineralization impairment. Little is known regarding the importance 
of osteoblast terminal differentiation in mineralization disturbances and the 
deterioration of bone mechanical properties leading to fragility fractures. Questions 
regarding bone formation disturbances in post-menopausal osteoporosis have recently 
arisen with the finding that oestrogen deficiency is linked to mineralization disturbances 
secondary to osteoblast impairment (87-90). In the elderly, some studies have shown 
that osteoblast dysfunction due to age-dependent decreases in IGF-1 and FGF-2 was 
associated with osteoporosis (55). Further insight into the importance of impaired 
osteoblast function in fragility fractures among the elderly is needed. In this thesis, we 
have filled this knowledge gap by analysing the association between bone OCL/COL1a1 
expression ratio and bone mechanical properties, as well as hip fractures.  
 
Fragility Fractures Risk Assessment 
A fragility fracture is not only caused by skeletal factors but also by extra-skeletal factors, 
such as a propensity to falls, soft tissue dysfunction, impact force, and impact surface. 
Clinical risk factors (e.g., age, sex, family history of fractures, chronic diseases, BMI) 
influence bone mechanical properties, propensity to falls, and muscle behaviour, but 
they do not explain entirely these other factors (Figure 5). Thus, assessment of fracture 
risk should involve a comprehensive approach accounting for the myriad of factors 
contributing to fragility fractures.  
Several tools have been developed to identify people at risk of fragility fractures. The 
most widely used are measurement of BMD, determination of serum levels of bone 
turnover markers, and the use of algorithms for fracture risk prediction that include 
clinical risk factors for fractures and BMD (e.g., FRAX tool, QFracture, Garvan risk 
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calculator) (91, 92). The development of these tools, especially fracture risk prediction 
algorithms, has improved the identification of individuals at high risk of fracture; 
however, these tools still fail to identify a substantial portion of women and men who 
will have a fragility fracture (93-95). 
 
 
Figure 5. Skeletal and extra-skeletal risk factors for fragility fractures. 
 
Dual x-ray absorptiometry 
DXA is used to assess BMD at the most vulnerable sites for fractures: the lumbar spine 
and hips. The WHO operational definition of osteoporosis is based on a reduction of 
BMD to 2.5 or more standard deviations (SDs) below the young adult norm, the T-score 
(96) (Table 1). In both men and women, low BMD is associated with a higher risk of 
fragility fractures, independent of age or fracture site (93, 97). Fracture risk increases 
2.6 fold for each SD decrease in hip BMD (97). Of note, site-specific BMD is a better 
predictor of fracture risk at that site; for example, hip fractures are better predicted by 
hip BMD than by vertebral BMD (93).  
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Table 1. World Health Organization diagnostic criteria for osteoporosis. 
BMD T-score Classification 
T-score ≥ -1 Normal 
- 2.5 < T-score < -1 Low bone mass 
T-score ≤ -2.5 Osteoporosis 
T-score ≤ -2.5 + fragility fracture Severe osteoporosis 
 
The association between BMD and fragility fractures is good but not perfect. In fact, the 
cut-off BMD value established by the WHO to clinically define osteoporosis fails to 
predict almost 50% of fragility fractures (93, 98). 
Over the past decade, both the hardware and software of DXA have improved, 
enhancing the reliability of BMD measurements. Additionally, introduction of high-
quality DXA 2-dimensional x-rays led to the development of the trabecular bone score 
(TBS) at the lumbar vertebra. TBS is a textural index that evaluates pixel grey-level 
variations in the lumbar spine DXA image, delivering an indirect index of trabecular 
microarchitecture (99). TBS is associated with bone mechanical intrinsic properties and 
bone strength (100, 101). Prospective studies revealed that TBS is also associated with 
fragility fractures, independent of BMD and clinical risk factors (102, 103). However, the 
predictive ability of TBS is modest. Like BMD, it can enhance fracture risk prediction if 
included in a comprehensive model of fracture risk determination (103, 104). 
 
Bone turnover markers  
Biochemical bone turnover markers reflect either the enzymatic activity of osteoblasts 
and osteoclasts or the breakdown products of bone tissue. Therefore, these markers 
can be valuable tools to investigate bone metabolism, monitor treatment efficacy, 
define treatment strategies, and assess fracture risk. The most widely used markers for 
bone formation are serum levels of alkaline phosphatase (ALP), bone-specific ALP, OCL, 
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and procollagen type I pro-peptides (P1CP and P1NP). Pyridinium crosslinks (PYD and 
DPD) and two type I collagen telopeptides (CTX and NTX) reflect bone resorption. 
Tartrate-resistant acid phosphatase 5b (TRAcP5b), cathepsin K (CTSK), bone sialoprotein 
(BSP), and the RANKL/OPG ratio (Figure 6) were recently identified as biomarkers for 
evaluating bone remodelling (105). Biochemical determination of bone turnover 
markers is an appealing way to identify people with a high risk of fracture, as samples of 
blood or urine are easily collected, and several inexpensive assays are now in the 
market.  
Serum levels of bone turnover markers reflect bone remodelling (106) and are 
associated with BMD (95, 107-110). Some studies reported a modest association with 
fragility fractures (95, 107-110), although others found that the association with fragility 
fractures was not independent of BMD (107, 110-113). Moreover, the available bone 
turnover markers have wide biological variability and, in some cases, multiple 
methodologies are used to test the same analyte (95). Therefore, new biological 
markers of bone metabolism that demonstrate added value in individual fracture risk 
assessment are necessary.  
Some studies suggested that serum levels of the Wnt regulators, in particular SOST and 
DKK1, could have a role in osteoporosis and in the identification of subjects at risk of 
developing osteoporosis. In fact, serum levels of DKK1 and SOST increase with age, and 
this is associated with loss of bone mass (77-79). Mirza and colleagues found that SOST 
serum levels were not only significantly higher in post-menopausal women, but they 
were also inversely associated with the free oestrogen index (80). In addition, treatment 
of post-menopausal osteoporosis (in both animal models and humans) with either anti-
SOST or anti-DKK1 antibodies led to increased bone formation, bone mass, and bone 
strength (81, 82, 114). Anti-SOST treatment also demonstrated efficacy in reducing 
fracture risk (115). In this thesis, we aimed to uncover the clinical utility of serum 
measurements of Wnt regulators and determine their association with fracture risk in a 
population-based nationwide cohort, the EpiDoC cohort. More importantly, we sought 
to understand whether serum levels of Wnt regulators could be used to improve 
fracture risk prediction when added to BMD and clinical risk factors.  
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Figure 6. Bone turnover markers. 
Bone turnover markers can be divided into bone formation and bone resorption markers. Formation 
markers derive from osteoblast metabolism, while resorption markers originate from osteoclast action. 
The RANKL/OPG ratio is a marker of osteoclastogenesis. The most reliable bone turnover markers are 
P1NP and CTX. (ALP, alkaline phosphatase; BSP, bone sialoprotein; CTSK, cathepsin K; CTX, carboxy-
telopeptide of type I collagen; DPD, deoxypyridinoline; NTX, amino-telopeptide of type I collagen; OCL, 
osteocalcin; OPG, osteoprotegerin; P1CP, procollagen 1 carboxy-terminal peptide; P1NP, procollagen 1 
amino-terminal peptide; PYD, pyridinoline; RANK, receptor activator of nuclear factor kappa B; RANKL, 
RANK ligand; TRAcP5b, tartrate-resistant acid phosphatase 5b.) 
 
Fracture risk prediction algorithm: FRAX tool 
Population-based cohorts from Europe, North America, Asia, and Australia identified 
clinical risk factors for fractures, which provided information about fracture risk 
independently of BMD (116-120) (Figure 7). Therefore, the importance of using clinical 
risk factors in addition to BMD information for predicting individual absolute fracture 
risk was clear to researchers (121). Several fracture prediction models have been 
created and validated; however, the FRAX model is the most widely validated and 
disseminated tool worldwide (92). The FRAX tool is an algorithm based on a multivariate 
model, which incorporates (in a weighted manner) the independent clinical risk factors 
for fracture (hip BMD, age, BMI, prior low-impact fracture, parental history of hip 
fracture, current smoking, alcohol intake, glucocorticoid use for more than 3 months, 
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rheumatoid arthritis, and other secondary causes of osteoporosis) in combination with 
the corresponding mortality rate for each country (Figure 7).  
 
Figure 7. FRAX® fracture risk assessment tool. 
 
FRAX was developed by researchers at Sheffield University to assess the 10-year 
probability of both major and hip fractures, with or without considering BMD. It was 
meant to be used for individuals more than 40 years of age with untreated osteoporosis. 
Overall, this tool demonstrated better performance than BMD in fragility fracture 
prediction (91). In fact, computing FRAX with only clinical risk factors has demonstrated 
similar performance to DXA alone in predicting non-hip fractures and better 
performance than DXA in predicting hip fractures (19, 122). If we consider just the senior 
population, FRAX calculated with only clinical risk factors is superior to BMD as a 
screening tool for identifying individuals with a high risk of fracture (91). A recent 
randomized controlled trial revealed that using the FRAX algorithm as a screening tool 
is feasible and effective in reducing the incidence of hip fractures. However, it has the 
same limitations as BMD screening in preventing other low-impact fractures (123). 
Recently, it became possible to adjust the FRAX output by incorporated vertebral spine 
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TBS measurements. This integrated model (FRAX+TBS) modestly increases the ability to 
predict fractures in individuals, compared with FRAX alone; it is most useful for younger 
adults (104). 
The FRAX tool has been available online since 2008 and can be used in 53 countries 
worldwide, based on country-specific calibration according to the national epidemiology 
of fractures and mortality rates (92). To accurately treat patients, it was necessary to 
define country-specific treatment thresholds for the FRAX prediction model. Several 
countries conducted cost-effectiveness analyses and defined pharmacological 
treatment thresholds for FRAX (124, 125). In 2013, a research group led by Professor 
Pereira da Silva et al. calibrated a FRAX model for Portugal, allowing FRAX to be used in 
clinical practice in this country (33). A few years later, in 2016, Marques et al. performed 
a cost-effectiveness analysis for different pharmacological treatments to define FRAX 
treatment thresholds in Portugal (126). This work of validating and defining cost-
effectiveness pharmacological treatment thresholds was of upmost importance to 
improve the selection of patients that would benefit from anti-osteoporotic therapy. To 
implement this new knowledge in clinical practice and improve the substantial 
constraints involved in the prevention, screening, and management of osteoporosis-
related fractures, it was necessary to develop national consensus recommendations. 
The work under the scope of this thesis encompassed the collaborative efforts in 
establishing multidisciplinary recommendations regarding the indications for DXA and 
for initiating medical therapy aimed at preventing fractures, as well as the efforts 
involved in developing an update of the Portuguese Society of Rheumatology’s 
recommendations regarding the prevention, diagnosis, and management of 
osteoporosis.  
 
Treatment Strategies for Osteoporosis and Fragility Fractures  
Osteoporosis is a multifactorial disease associated with low peak bone mass and/or 
rapid and persistent bone loss. In addition, overlapping effects of many concomitant 
chronic diseases and medications also contribute to excessive and/or imbalanced bone 
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remodelling, promoting further loss of bone mass and microarchitectural deterioration. 
Factors such as insufficient sun exposure, inadequate nutrient intake (of calcium, 
vitamin D, and protein), limited exercise, and high-risk behaviours (smoking and 
excessive alcohol consumption) also play a role in low peak bone mass and loss of bone 
(116, 120, 127-130). Therefore, the optimal approach for treating osteoporosis involves 
both pharmacological and non-pharmacological measures. 
Adequate nutrition with a well-balanced diet, sufficient sun exposure, and regular 
weight-bearing exercise are important measures that promote bone health in the 
general population, and especially in patients with osteoporosis (Figure 8) (131).  
 
 
Figure 8. Non-pharmacological osteoporosis treatment. 
 
Several drugs with demonstrated efficacy, safety, and cost-effectiveness are available 
for the treatment of osteoporosis (Table 2) (126, 132-145). Fracture risk reduction 
associated with these pharmacological treatments varies between 20% and 83%, 
depending on the drug and fracture site. However, despite this plethora of osteoporosis 
treatments, in many European countries and the United States of America, fewer than 
25% of patients with major osteoporosis-related fractures are treated for their 
underlying osteoporosis (146). In Portugal, no information is available regarding the 
diagnosis and treatment rates of osteoporosis in women who have sustained a fragility 
fracture. In this thesis, we aimed to improve knowledge and understanding of this highly 
relevant topic. Moreover, we developed clinical consensus recommendations regarding 
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osteoporosis treatment strategies, with the goal of contributing to improved 
osteoporosis treatment in Portugal.  
 
 
Table 2. Evidence regarding efficacy and safety of pharmacological treatments for 
patients with osteoporosis (Adapted from the American College of Physicians Clinical Guideline of 
osteoporosis treatment (147)). 
Treatment Effect on fracture risk  Adverse effects Vertebral Non-vertebral Hip 
Alendronate + + + Mild gastrointestinal symptoms ¥ 
Ibandronate + ? ? Mild gastrointestinal symptoms; myalgia¥ 
Residronate + + + Mild gastrointestinal symptoms ¥ 
Zoledronic Acid + + + Mild gastrointestinal symptoms; hypocalcaemia; flu-like symptoms ¥ 
Denosumab + + + Mild gastrointestinal symptoms; infections; cutaneous rash¥ 
Teriparatide + + ? Mild gastrointestinal symptoms; hypocalcaemia; headache 
Raloxifene + - - Hot flashes; thromboembolic events 
Non-vertebral refers to fractures not occurring in the spine or skull. 
+ refers to efficacy demonstrated in randomized control trials. - refers to no efficacy demonstrated in 
randomized control trials. ? refers to unknown efficacy in original trials or efficacy shown only during post 
hoc analysis. ¥ indicates that atypical femoral fractures and jaw osteonecrosis are very rare adverse events 
with bisphosphonates and denosumab in patients with osteoporosis (148). 
 
In conclusion, the adverse consequences of osteoporosis and fragility fractures are being 
increasingly recognized. However, several unmet research needs remain regarding 
fracture risk stratification of patients, disease mechanisms, and new treatment strategies. 
To overcome the complex problems of predicting and managing fragility fractures, we 
hypothesize that establishing national epidemiological knowledge regarding osteoporosis 
and fragility fractures will provide evidence to customize national health care solutions. 
We also hypothesize that fracture risk assessment can be refined by the use of serum 
biomarkers. Clinical consensus recommendations, using the best evidence in clinical 
practice, will be also an important tool to improve the identification and management of 
patients with a high risk of fragility fracture. 
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CHAPTER II - GENERAL AND SPECIFIC AIMS 
 
In this thesis, we aimed to answer three questions, which reflect current unmet research 
needs: 
1) What are the prevalence, burden, and risk factors of osteoporosis and fragility 
fractures in Portugal? 
2) How can we better identify people at risk of fragility fractures? 
3) Can we establish national clinical consensus recommendations to improve 
individual clinical assessment?  
 
General Aims 
 
With this PhD thesis, we aimed to address the prevalence and burden of osteoporosis 
and fragility fractures in Portugal to provide objective evidence to support new health 
strategies, improve clinical care, and reduce or prevent disability and mortality.  
We also aimed to improve the identification of senior women (aged ≥65 years old) at 
high risk for a fragility fracture through the use of novel noninvasive biomarkers. To 
achieve this goal, we explored cellular (osteoblast) mechanism dysfunction to identify 
potential serum markers of bone fragility. We hypothesized that bone fragility in the 
elderly is associated with dysregulation of osteoblast terminal differentiation and 
disturbances in Wnt regulators (DKK1, DKK2, SOST, WIF-1, and sFRP-1). Moreover, we 
hypothesized that serum levels of Wnt regulators are associated with bone fragility and 
fractures and can constitute new markers for osteoporosis treatment decision-making.  
Finally, we aimed to develop national clinical consensus recommendations for 
osteoporosis diagnosis and treatment to create awareness and reduce new fragility 
fractures in Portugal. 
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Specific Aims 
AIM 1: To estimate the prevalence and burden of osteoporosis in Portugal. 
AIM2: To estimate the prevalence, risk factors, and burden of fragility fractures, as well 
as the prescription of and compliance with anti-osteoporotic drug treatment, among 
older Portuguese women (a vulnerable high-risk stratum).  
AIM 3: To identify clinical risk factors associated with poor mechanical properties among 
patients with fragility fractures. 
AIM 4: To analyse whether osteoblast disturbances, measured by gene expression of 
OCL/COL1A1 in bone (a surrogate marker of osteoblast terminal differentiation), are 
associated with bone mechanical behaviour and fragility fractures. 
AIM 5: To analyse whether serum levels of Wnt regulators (DKK1, DKK2, SOST, WIF-1, 
and sFRP-1), as controllers of osteoblast differentiation, are independently associated 
with axial bone mineral mass evaluated by DXA and incident fragility fractures, using a 
population-based nationwide cohort of senior women.  
AIM 6: To develop national clinical consensus recommendations regarding osteoporosis 
diagnosis and treatment to reduce the incidence of fragility fractures in Portugal. 
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METHODOLOGY  
 
For this thesis, we used two samples of participants/patients. One sample was 
composed of patients who underwent hip replacement surgery for osteoarthritis or 
fragility fracture from 2008 to 2012 at the Orthopaedic Department of Centro Hospitalar 
Lisboa Norte. The other sample was a population-based nationwide sample evaluated 
by survey in the EpiReumaPt study (2011-2013). The EpiReumaPt population was 
subsequently followed in two more waves of evaluation (2011-2016) under the scope 
of the Epidemiology of Chronic Diseases (EpiDoC) cohort. This chapter summarizes 
relevant aspects of the methodology used for this thesis. For each research question, a 
description is provided of the population of interest (i.e., subpopulations used), 
recruitment, study design, and case definition. This chapter also describes the work 
performed by the PhD student in each of these projects. For the EpiReumaPt survey and 
EpiDoC cohort, a comprehensive methodological approach was used and prepared for 
publication in separate manuscripts written by the PhD student as the first author. They 
are presented in distinct sections of this chapter.  
 
1. Convenience sample of patients undergoing hip replacement surgery 
In our research, we aimed to study bone biomechanics and cellular dysfunction in 
patients with hip fractures. This mechanistic approach enabled us to identify potential 
biomarkers of bone fragility and fractures. To achieve this aim, we studied a sample of 
consecutive patients who underwent total hip replacement surgery within 8 days after 
a hip fragility fracture at the Orthopaedic Department of Hospital de Santa Maria in 
Lisbon, between 2008 and 2012. We also included patients with osteoarthritis referred 
for total hip replacement surgery during the same period as a comparison group. A 
clinical protocol was used, which included determining the presence or absence of 
clinical risk factors for fracture. Fasting blood samples and spine and hip BMD 
measurements were obtained. Femoral epiphyses were collected, from which 
trabecular bone cylinders were obtained for use in compression mechanical tests. Gene 
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expression of bone matrix components was assessed by quantitative real-time 
polymerase chain reaction (RT-PCR) analysis.  
Under the scope of this research, two manuscripts (Chapter IV, Section II, Part 1, and 
Part 2) were prepared and published in peer-reviewed journals. The manuscript 
presented in Chapter IV, Section II, Part 1 aimed to analyse clinical risk factors associated 
with poor mechanical behaviour in patients with hip fragility fractures. The manuscript 
presented in Chapter IV, Section II, Part 2 aimed to analyse the association between 
osteoblast terminal differentiation and fragility fractures, as well as poor trabecular 
mechanical behaviour.  
Both studies used the same inclusion and exclusion criteria. The inclusion criteria were 
age 50 years or older and/or a post-menopausal woman, able to provide clinical 
information, and able to provide written informed consent. The exclusion criteria were 
receiving anti-osteoporotic therapy; being out of the range for calculating the 10-year 
risk of major/hip fracture using the FRAX algorithm (age and BMI); or having a personal 
history of other bone metabolic diseases (other than osteoporosis), bone metastasis, a 
primary tumour, or osteomyelitis. Although we used the same inclusion and exclusion 
criteria for both studies, the samples were not the same because in the first study 
(Chapter IV, Section II, Part 1), we used data collected between 2008 and 2009, and for 
the second study (Chapter IV, Section II, Part 2), we used data collected between 2009 
and 2012. 
The PhD student contributed to the design and conduct of the study, and applied the 
clinical protocol for all samples. The student also performed data management, data 
analysis (the PhD student takes responsibility for the integrity of the data analysis 
presented in these papers), and data interpretation. The student likewise drafted and 
revised the manuscripts and submitted the final version of each manuscript. Both papers 
were published in international peer-reviewed journals.  
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2. EpiReumaPt survey  
For this thesis, we also aimed to determine the prevalence of osteoporosis in Portugal 
and define the burden of fragility fractures and the osteoporosis treatment rates among 
senior women (aged ≥65 years old). For this, we used data from the EpiReumaPt study 
(Chapter IV, Section I, Part 1, and Part 2). 
The EpiReumaPt cohort is composed of a randomly selected, representative sample of 
the adult Portuguese population in mainland Portugal, the Azores Islands, and the 
Madeira Islands. Recruitment started in September 2011 and finished in December 
2013. EpiReumaPt aimed to estimate the prevalence of RMDs in the adult Portuguese 
population. The selected diseases were hand, knee, and hip osteoarthritis; low back 
pain; rheumatoid arthritis; fibromyalgia; gout; spondyloarthritis; periarticular disease; 
systemic lupus erythematosus; polymyalgia rheumatica; and osteoporosis.  
The study design involved a three-stage approach. The first step was a face-to-face 
survey performed by trained interviewers at the household of 10,661 subjects who were 
randomly selected by stratified multistage sampling. A highly sensitive screening 
questionnaire for RMDs was used. Secondly, participants who screened positive (64%) 
for at least one RMD, as well as 20% of those with a negative screening, were invited for 
an assessment by a rheumatologist and were asked to donate a blood sample to be 
stored at the Biobanco-IMM, Lisbon Academic Medical Centre. In total, 3,877 subjects 
participated in this second phase. The rheumatologist performed a medical history and 
physical examination and obtained appropriate laboratory and imaging tests. At the end 
of the visit, the rheumatologist established a diagnosis. Finally, a team of three 
experienced rheumatologists reviewed all of the clinical data and defined the diagnoses 
according to previously validated criteria.  
The EpiReumaPt sample was composed of adults (≥ 18 years old) who were living in 
private households in Portugal (mainland, Madeira Islands, or Azores Islands). 
Osteoporosis was defined by the diagnosis of an expert (the rheumatologist), which was 
based on the presence of at least of one of the following: previous fragility fracture, 
previous diagnosis of osteoporosis, osteoporosis treatment, or fulfilment of WHO 
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criteria (when axial DXA data were available).  
Our research question was under the scope of the EpiReumaPt study and results were 
published along with the prevalence and burden of other RMDs in a paper in which the 
PhD student was the second author and participated in the following: data collection 
(one-third of the EpiReumaPt clinical appointments), study conduct, data management, 
data analysis (the PhD student takes responsibility for the integrity of the data analysis 
presented in the paper), data interpretation, manuscript drafting and revisions, and 
approval of the final version of the manuscript (Chapter IV, Section I, Part 1).  
In the manuscript presented in Chapter IV, Section I, Part 2, we also used EpiReumaPt 
data to study the prevalence, burden, risk factors, and osteoporosis treatment rates of 
fragility fractures among Portuguese senior women. The population of interest was 
defined as women 65 years and older who participated in the second phase of 
EpiReumaPt (Figure 9). Fragility fractures were defined as any self-reported, low-impact 
fracture (fractures resulting from a fall from a standing height or less or occurring in the 
absence of any trauma) in individuals older than 40 years. Fractures of the face, skull, 
foot, fingers, and toes were excluded.  
In this work, the PhD student was responsible for formulation of the research question, 
data management, data analysis (the PhD student takes responsibility for the integrity 
of the data analysis presented in the paper), data interpretation, manuscript drafting 
and revisions, approval of the final version of the manuscript, and submission of the 
manuscript, which was published in an international peer-reviewed journal. 
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Figure 9. Study design flowchart of the research addressing the prevalence and burden 
of fragility fractures in senior Portuguese women.  
 
3. EpiDoC cohort  
Using data from the EpiDoC cohort, we analysed whether serum levels of Wnt regulators 
(masters of osteoblast differentiation)—including DKK1, DKK2, SOST, WIF-1, and sFRP—
are independently associated with axial bone mineral mass evaluated by DXA or with 
incident fragility fractures in senior women.  
The EpiDoC cohort was composed by EpiReumaPt participants who agreed to be 
followed (n=10,153) and who completed the three waves of the study. In each wave, a 
core questionnaire regarding socioeconomic status, RMDs, fractures, falls, other chronic 
diseases, quality of life, and healthcare resource consumption was employed to gather 
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longitudinal data. Each wave also had specific questions regarding other health and 
health-related issues, allowing the collection of cross-sectional and longitudinal data. 
The first wave, the EpiReumaPt study (2011-2013), was described above. The follow-up 
waves (second and third) involved telephone call interviews performed by research 
assistants. The second wave (EpiDoC 2, 2013–2015) collected data regarding lifestyles, 
lifestyle determinants, and innovative patient solutions for coping with disability, and 
the third wave (EpiDoC 3, 2015–2016) evaluated inequalities in access to food and 
healthcare services.  
To identify new serum markers of bone fragility in senior women, we used a 
subpopulation of the EpiDoC cohort, defined as women 65 years and older who 
participated in the second phase of EpiReumaPt and agreed to be followed (Figure 10). 
The exclusion criteria were receiving osteoporosis treatment or having bone metastasis 
or any metabolic bone disease except osteoporosis. The manuscripts for this study are 
presented in Chapter IV, Section III, Part 1. 
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Figure 10. Flowchart of study population and participant retention during follow-up for 
research analysing Wnt regulators as biomarkers of bone mineral density and fragility 
fractures.  
The PhD student was responsible for developing the follow-up protocol for the EpiDoC 
cohort and for designing and testing the questionnaires used in the phone call interviews 
for EpiDoC 2 and 3. The student also monitored data acquisition and developed 
strategies to reduce missing data. In addition, the student performed data management, 
data analysis, and data interpretation; drafted and revised the manuscript; and 
prepared and submitted the final version of the manuscript. The PhD student takes full 
responsibility for the integrity of the data analysis, data interpretation, and the 
manuscript presented in Chapter IV, Section III, Part 1. 
 

  
 
- 75 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPIREUMAPT STUDY DESCRIPTION 
 
RODRIGUES AM, GOUVEIA N, DA COSTA LP, ET AL. 2015. EPIREUMAPT – THE STUDY OF RHEUMATIC AND 
MUSCULOSKELETAL DISEASES IN PORTUGAL: A DETAILED VIEW OF THE METHODOLOGY. ACTA REUMATOL 
PORT. 40:110-124 

  
 
 
- 77 - 
EPIREUMAPT STUDY DESCRIPTION 
CHAPTER III 
 
 
- 78 - 
 
METHODOLOGY 
 
 
- 79 - 
 
 
CHAPTER III 
 
 
- 80 - 
 
METHODOLOGY 
 
 
- 81 - 
 
 
CHAPTER III 
 
 
- 82 - 
 
METHODOLOGY 
 
 
- 83 - 
 
CHAPTER III 
 
 
- 84 - 
 
METHODOLOGY 
 
 
- 85 - 
 
CHAPTER III 
 
 
- 86 - 
 
METHODOLOGY 
 
 
- 87 - 
 
CHAPTER III 
 
 
- 88 - 
 
METHODOLOGY 
 
 
- 89 - 
 
CHAPTER III 
 
 
- 90 - 
 
METHODOLOGY 
 
 
- 91 - 
 

  
 
- 93 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EPIDOC COHORT DESCRIPTION 
 
 
DIAS SS*, RODRIGUES AM*, GREGÓRIO MJ, ET AL. 2018 COHORT PROFILE: EPIDEMIOLOGY OF CHRONIC 
DISEASES COHORT (EPIDOC). INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 

  
 
- 95 - 
EPIDOC COHORT DESCRIPTION 
 
 
CHAPTER III 
 
 
- 96 - 
 
 
  
METHODOLOGY 
 
 
- 97 - 
 
  
CHAPTER III 
 
 
- 98 - 
 
  
METHODOLOGY 
 
 
- 99 - 
 
  
CHAPTER III 
 
 
- 100 - 
 
  
METHODOLOGY 
 
 
- 101 - 
 
  
CHAPTER III 
 
 
- 102 - 
 
METHODOLOGY 
 
 
- 103 - 
 
  
CHAPTER III 
 
 
- 104 - 
 
  
METHODOLOGY 
 
 
- 105 - 
 
  
CHAPTER III 
 
 
- 106 - 
 
 
  
 
- 107 - 
 
 
 
 
 
 
 
CHAPTER IV 
 
RESULTS 
SECTION I – PREVALENCE, BURDEN AND UNDERTREATMENT OF 
OSTEOPOROSIS AND FRAGILITY FRACTURES IN PORTUGAL 
SECTION II – CLINICAL RISK FACTORS AND CELLULAR DISTURBANCES 
ASSOCIATED WITH POOR TRABECULAR MECHANICAL BEHAVIOUR AND WITH 
HIP FRACTURES 
SECTION III – SURROGATE MARKERS OF BONE MINERAL DENSITY AND 
FRACTURES IN A POPULATION BASED LONGITUDINAL COHORT 
SECTION IV – STRATEGIES TO REDUCE NEW FRAGILITY FRACTURES IN 
PORTUGUESE POPULATION

  
 
- 109 - 
CHAPTER IV - RESULTS 
  
 
 
 
SECTION I 
 PREVALENCE, BURDEN AND UNDERTREATMENT OF OSTEOPOROSIS AND 
FRAGILITY FRACTURES IN PORTUGAL 
 
PART 1 – BRANCO JC, RODRIGUES AM, GOUVEIA N, ET AL. 2016. PREVALENCE OF RHEUMATIC DISEASES 
AND MUSCULOSKELETAL DISEASES AND THEIR IMPACT ON HEALTH-RELATED QUALITY OF LIFE, PHYSICAL 
FUNCTION AND MENTAL HEALTH IN PORTUGAL: RESULTS FROM EPIREUMAPT – A NATIONAL HEALTH 
SURVEY. RMD OPEN. 2:E000166. 
 
PART 2 – RODRIGUES AM, EUSÉBIO M, SANTOS MJ, ET AL. 2018. THE BURDEN OF UNDERTREATMENT 
FRAGILITY FRACTURES AMONG SENIOR WOMEN. ARCHIVES OF OSTEOPOROSIS. 13:22. 

  
 
- 111 - 
SECTION I, PART 1 
 
CHAPTER IV 
 
 
- 112 - 
 
 
 
SECTION I, PART 1 
 
 
- 113 - 
 
 
 
CHAPTER IV 
 
 
- 114 - 
 
 
 
SECTION I, PART 1 
 
 
- 115 - 
 
 
 
CHAPTER IV 
 
 
- 116 - 
 
 
 
SECTION I, PART 1 
 
 
- 117 - 
 
 
 
CHAPTER IV 
 
 
- 118 - 
 
 
 
SECTION I, PART 1 
 
 
- 119 - 
 
 
 
CHAPTER IV 
 
 
- 120 - 
 
 
 
SECTION I, PART 1 
 
 
- 121 - 
 
 
 
CHAPTER IV 
 
 
- 122 - 
 
 
  
 
- 123 - 
SECTION I, PART 2 
CHAPTER IV 
 
 
- 124 - 
 
 
 
SECTION I, PART 2 
 
 
- 125 - 
 
 
 
CHAPTER IV 
 
 
- 126 - 
 
 
 
SECTION I, PART 2 
 
 
- 127 - 
 
 
 
CHAPTER IV 
 
 
- 128 - 
 
 
 
SECTION I, PART 2 
 
 
- 129 - 
 
 
 
CHAPTER IV 
 
 
- 130 - 
 
 
 
SECTION I, PART 2 
 
 
- 131 - 
 
 
 
CHAPTER IV 
 
 
- 132 - 
 
 
 
SECTION I, PART 2 
 
 
- 133 - 
 
 
 
CHAPTER IV 
 
 
- 134 - 
 
 
 
SECTION I, PART 2 
 
 
- 135 - 
 
 
CHAPTER IV 
 
 
- 136 - 
 
 
 
  
 
- 137 - 
 
 
 
 
SECTION II 
CLINICAL RISK FACTORS AND CELLULAR DISTURBANCES ASSOCIATED WITH 
POOR TRABECULAR MECHANICAL BEHAVIOUR AND WITH HIP FRACTURES 
 
PART 1 - RODRIGUES AM, CAETANO-LOPES J, VALE AC, ET AL. 2012. SMOKING IS A PREDICTOR OF WORSE 
TRABECULAR MECHANICAL PERFORMANCE IN HIP FRAGILITY FRACTURE PATIENTS. J BONE MINER METAB. 
30(6):692-699. 
 
PART 2 – RODRIGUES AM, CAETANO-LOPES J, VALE AC, ET AL. 2012. LOW OSTEOCALCIN/COLLAGEN TYPE 
I BONE GENE EXPRESSION RATIO IS ASSOCIATED WITH HIP FRAGILITY FRACTURES. BONE. 51:981-989. 
 

  
 
- 139 - 
SECTION II, PART 1 
 
CHAPTER IV 
 
 
- 140 - 
 
 
 
SECTION II, PART 1 
 
 
- 141 - 
 
 
 
CHAPTER IV 
 
 
- 142 - 
 
 
 
SECTION II, PART 1 
 
 
- 143 - 
 
 
 
CHAPTER IV 
 
 
- 144 - 
 
 
 
SECTION II, PART 1 
 
 
- 145 - 
 
 
 
CHAPTER IV 
 
 
- 146 - 
 
  
 
- 147 - 
SECTION II, PART 2 
 
 
CHAPTER IV 
 
 
- 148 - 
 
 
 
 
SECTION II, PART 2 
 
 
- 149 - 
 
 
 
 
CHAPTER IV 
 
 
- 150 - 
 
 
 
 
SECTION II, PART 2 
 
 
- 151 - 
 
 
 
 
CHAPTER IV 
 
 
- 152 - 
 
 
 
 
SECTION II, PART 2 
 
 
- 153 - 
 
 
 
 
CHAPTER IV 
 
 
- 154 - 
 
 
 
 
SECTION II, PART 2 
 
 
- 155 - 
 
 

  
 
- 157 - 
 
 
 
 
 
SECTION III 
SURROGATE MARKERS OF BONE MINERAL DENSITY AND FRACTURES IN A 
PORTUGUESE POPULATION BASED LONGITUDINAL COHORT 
 
PART 1 – RODRIGUES AM, EUSÉBIO M, RODRIGUES AB ET AL. LOW SERUM LEVELS OF DKK2 ARE A 
POTENTIAL SERUM MARKER OF INCIDENT LOW IMPACT FRACTURE RISK IN OLDER WOMEN. (SUBMITTED TO 
JBMR PLUS). 

  
 
- 159 - 
SECTION III, PART 1 
 
Low Serum Levels of DKK2 are a potential serum marker of Incident Low Impact 
Fractures Risk in Older Women 
Ana Maria Rodrigues, Mónica Eusébio, Ana C Rodrigues, Joana Caetano-Lopes, Inês P 
Lopes, Ana Lopes, Jorge M Mendes, Pedro Simões Coelho, João Eurico Fonseca, Jaime 
Branco, Helena Canhão 
(Submitted to JBMR Plus) 
 
Abstract 
There are currently no robust non-invasive markers of fragility fractures. Secreted frizzled 
related protein-1 (sFRP-1), dickkopf-related protein 1 (DKK1) and DKK2, and sclerostin (SOST) 
inhibit Wnt signalling and interfere with osteoblast-mediated bone formation. We evaluated 
associations of serum levels of sFRP-1, DKK1, DKK2, and SOST with incident low-impact fracture 
and BMD in 828 women aged ≥65 years from EpiDoC, a longitudinal population-based cohort. A 
structured questionnaire during a baseline clinical appointment assessed prevalent fragility 
fractures and clinical risk factors (CRFs) for fracture. Blood was collected to measure serum 
levels of bone turnover markers and Wnt regulators. Vertebral and hip BMD were determined 
by DXA scanning. Follow-up assessment was performed through phone call interview; incident 
fragility fracture was defined by any new self-reported low-impact fracture. Multivariate Cox 
proportional hazards models were used to analyse fracture risk adjusted for CRFs and BMD. 
During a mean follow-up of 2.3±1.0 years, 62 low-impact fractures were sustained in 58 women. 
A low serum DKK2 level (per 1 SD decrease) was associated with a 1.5-fold increase in fracture 
risk independently of BMD and CRFs. Women in the two lowest DKK2 quartiles had a fracture 
incidence rate of 32 per 1,000 person-years, whereas women in the two highest quartiles had 
14 fragility fractures per 1,000 person-years. A high serum sFRP1 level was associated with a 
1.6-fold increase in fracture risk adjusted for CRFs but not independently of BMD. Serum levels 
of SOST (r=0.191; p=0.0025) and DKK1(r=-0.1725; p=0.011) were correlated with hip BMD but 
not with incident fragility fracture. These results indicate that serum DKK2 and sFRP1 may 
predict low-impact fracture and suggest that Wnt pathway regulators should be further studied 
in other populations as potential non-invasive markers of fragility fracture risk.  
Key words: Fracture risk assessment, Screening, Molecular pathways - remodelling, Wnt/β-
catenin/LRPs, Aging 
Introduction 
Osteoporosis is a metabolic skeletal disease 
characterized by low bone mass and 
microarchitecture deterioration that 
frequently affects older adults(1,2). The 
clinical consequence of osteoporosis is the 
occurrence of low-impact fractures, 
resulting in increased mortality, morbidity, 
and disability and imposing a major 
economic burden on European healthcare 
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systems(3,4). One strategy for preventing 
osteoporosis-related fractures is to refine 
tools for identifying individuals with a high 
risk of fracture, as almost half of all 
fractures occur in individuals who are not 
classified as high risk by DXA scanning (5). To 
improve fracture risk assessment, several 
algorithms have been developed and 
validated(6-9). These include clinical risk 
factors (CRFs) such as age, gender, BMI, 
prior fragility fracture, parental history of 
hip fracture, use of oral glucocorticoids, 
rheumatoid arthritis and other secondary 
causes of osteoporosis, current smoking 
and alcohol intake to predict low-impact 
fracture, independently of BMD (10-14). 
Although the performance of these fracture 
risk prediction tools is good, there is room 
for improvement in sensitivity and 
specificity(15-17). The clinical challenge faced 
today is the accurate selection of individuals 
with a high risk of fracture and with 
indication for treatment to minimize 
individual and societal costs(1,5).   
Serum assays for biochemical markers are 
important for monitoring alterations in 
bone formation and resorption, both in 
normal physiological conditions and in 
disease. Bone turnover markers (BTMs) 
reflecting bone remodelling(18) are modestly 
associated with fracture risk(19-23). However, 
uncertainty exists regarding the clinical 
application of BTMs, as they exhibit short 
and long-term within-subject variability, 
and their usefulness for fracture prediction 
remains to be determined(22,24). Thus, new 
biochemical markers of bone metabolism 
that better predict low-impact fracture are 
needed.  
Recent studies show the importance of Wnt 
signalling to osteoblast differentiation(25-31). 
The most well-studied secreted Wnt 
antagonists are sclerostin (SOST), dickkopfs 
(DKKs), and secreted frizzled related 
proteins (sFRPs), which regulate osteoblast-
mediated bone formation(32). Some Wnt 
antagonists have been considered not only 
as treatment targets(33-35) but also as 
potential markers of bone fragility. Serum 
levels of DKK1 and SOST increase with age 
and are associated with loss of bone 
mass(36,37). sFRP-1 overexpression decreases 
bone density and attenuates the bone 
anabolic effects of PTH(38). DKK2 can either 
behave as a Wnt agonist or antagonist, 
depending on the cellular context(39). DKK2 
inhibits bone formation in the absence of 
Wnt7b but induces terminal osteoblast 
differentiation in the presence of high 
Wnt7b levels(40). Also, DKK2-null mice are 
osteopenic with suppressed bone 
formation(41). Currently, however, there are 
conflicting results regarding the association 
between serum levels of DKK1 and SOST 
and low-impact fractures(42-46), and, to the 
best of our knowledge, no studies have 
addressed the associations of DKK2 and 
sFRP-1 with fracture. 
The aim of the present study was to 
evaluate the association of serum levels of 
SOST, DKK1, DKK2, and sFRP-1 with BMD, 
and the incidence of low-impact fractures in 
elderly women from a population-based 
cohort. 
 
Materials and Methods 
Participants   
This study was conducted as part of the 
Epidemiology of Chronic Diseases (EpiDoC) 
cohort initiated in 2011. EpiDoC is a 
prospective closed cohort study based on a 
nationally representative sample of adults 
(≥18 years old) who were non-
institutionalized and living in private 
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households in Portugal Mainland and 
Islands (Azores and Madeira). The primary 
aim of the baseline assessment EpiDoC 1 
(EpiReumaPt), which occurred between 
September 2011 and December 2013, was 
to assess rheumatic and musculoskeletal 
disease prevalence and burden in Portugal. 
Multistage random sampling was used for 
participant selection. Baseline assessment 
consisted of two phases: the first phase 
involved a face-to-face interview, and the 
second phase involved a detailed clinical 
evaluation of rheumatic and 
musculoskeletal disease performed by a 
rheumatologist. All participants enrolled in 
EpiDoC 1 (n=10,661) were invited to 
participate in follow-up, of whom 10,153 
(95.2%) agreed to participate.  
For follow-up waves EpiDoC 2 (2013–2015) 
and EpiDoC 3 (2015–2016), data were 
collected using a structured questionnaire 
through phone call interviews using a 
computer- assisted personal interview 
system. In each follow-up interview, 
research assistants applied a nuclear 
questionnaire (including questions on new 
rheumatic disease onset, new fragility 
fractures, falls, medical treatment, and 
hospitalisations) and additional questions 
for each wave depending on its focus.  
Necessary sample size was calculated 
considering the primary aim of EpiDoC 1, 
which was to determine the prevalence of 
rheumatoid arthritis with 95% CIs 
standardized for age and gender according 
to the total adult population of the studied 
areas. Assuming an expected prevalence of 
rheumatoid arthritis of 0.5–1% and a drop-
out rate of 50%, a total of 9,000 participants 
needed to be recruited. We recruited 
10,661 participants. 
Study population 
The population of interest for the 
present study was women aged ≥65 
years who were observed by 
rheumatologists during the second 
phase of the baseline EpiDoC 1 
assessment and agreed to be followed 
up in subsequent EpiDoC waves. Full 
description of this population is provided 
elsewhere(47). Women under 
osteoporosis treatment or diagnosed 
with bone metastasis or other bone 
metabolic diseases, such as Paget’s 
disease of bone, were excluded from this 
study.   
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Figure 1. Flowchart of study participants. 
Outcome definition and assessment 
Fragility fracture events were defined as 
any self-reported low-impact fracture 
occurring after 40 years of age, including 
fractures resulting from a fall from a 
standing height or sustained fractures in 
the absence of trauma(48,49). Self-reports 
of fragility fractures have been shown to 
be accurate(50-52). Incident fractures were 
defined as self-reported new fractures 
during the two follow-up waves. The 
follow-up period was computed as the 
time from the baseline visit to a report of 
incident fracture. 
Covariate definition and assessment 
CRFs for fracture including age, BMI 
(categorized as underweight: <18.5 kg/m2, 
normal weight: 18.5–24.9 kg/m2, 
overweight: 25–29.9 kg/m2, or obese: ≥30 
kg/m2), parental history of hip fracture, 
long-term use of oral glucocorticoids (³3 
months), rheumatoid arthritis, current 
smoking, high alcohol intake (³3 units/day), 
other secondary causes of osteoporosis, 
and number of falls in the previous 12 
months were collected at baseline. Self-
reported previous fragility fractures (i.e., 
prevalent fragility fractures) were also 
recorded at baseline. Ten-year probability 
of major hip fracture was calculated using 
the Fracture Risk Assessment (FRAX) tool(53) 
without using hip DXA information.   
DXA procedure 
All women aged ≥65 years who attended 
the second phase of the baseline 
assessment were invited to undergo 
lumbar and non-dominant hip BMD 
measurement (g/cm2) using DXA 
scanning (Hologic QDR 4500 A, Bedford, 
MA, USA). Quality control procedures 
were performed according to the 
manufacturer´s recommendations. 
Biochemical assessment 
Blood samples were collected at 
baseline(54). Serum was separated by 
centrifugation (800g for 10 minutes at room 
temperature) and kept at 4ºC. Serum 
samples were sent to a central diagnostic 
laboratory to determine levels of bone 
remodelling markers, 25-hydroxyvitamin 
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D3, intact PTH, and creatinine. The 
remaining samples were stored at -80ºC at 
Biobanco-IMM(54,55).  
At the central lab, parameters were 
measured according to manufacturers’ 
instructions. Serum levels of creatinine 
were measured using the rate-blanked 
creatinine method (Dimension Vista 
Intelligent Lab System, Siemens Healthcare, 
Erlangen, Germany), and glomerular 
filtration rate was calculated(56). Serum 
levels of PTH, osteocalcin, crosslinked C-
telopeptide of type I collagen (CTX-I), and 
amino-terminal propeptides of type I 
procollagen (P1NP) were measured using a 
fully automated Immulite 2000® 
electrochemiluminescent immunoassay 
analyser (Siemens Healthcare, Germany). 
Serum levels of 25-hydroxyvitamin D3 were 
measured using competitive immunoassay 
(Liason Analyser, DiaSorin, Saluggia, Italy).  
Measurement  of Wnt signalling pathway 
regulators  
Levels of Wnt signalling regulators were 
assessed in serum samples stored at 
Biobanco-IMM (55). Baseline serum levels of 
sFRP-1 (Cloud-Clone Corp., Katy, TX, USA), 
DKK2 (Elabscience, Wuhan, China), DKK1 
(Biomedica Medizinprodukte, Vienna, 
Austria), and SOST (Biomedica 
Medizinprodukte) were determined by 
commercially available ELISA according to 
the manufacturers’ instructions and were 
analysed using a Tecan Infinite 200 PRO 
plate reader (Tecan, Männedorf, 
Switzerland). 
Statistical Analysis 
Data are presented as mean ± SD or 
frequency and proportion unless stated 
otherwise. Baseline characteristics of 
participants with and without incident 
fragility fracture were compared using 
univariable logistic regression analysis. 
Associations between serum levels of Wnt 
signalling regulators (sFRP-1, DKK2, DKK1, 
and SOST) and continuous or T-score 
categories of axial BMD (lumbar and non-
dominant hip) were analysed using Pearson 
correlations. Associations between serum 
levels of Wnt signalling regulators and BMD 
were analysed by univariable linear 
regression and adjusted for age, BMI, family 
history of hip fracture, physical activity, and 
glucocorticoid use. Associations between 
serum levels of Wnt signalling regulators 
and incident fragility fracture were analysed 
using Cox’s proportional hazards models 
with serum levels of Wnt signalling 
regulators as continuous or standardized 
(per 1 SD) measures. Fracture risk estimates 
were adjusted for age, family history of hip 
fracture, and prevalent fragility fracture. 
Adjustment for lumbar and hip BMD was 
performed in a separate Cox regression 
model.  
To further identify high-risk sub-groups of 
women for incident fragility fracture, serum 
levels of DKK2 and sFRP-1 were categorized 
into quartiles. The relationship between 
DKK2 (ng/mL) quartile and incident fracture 
rate (per 1,000 person-years) was assessed 
and adjusted for age, family history of hip 
fracture, prevalent fragility fracture, and hip 
BMD. The relationship between sFRP-1 
(ng/mL) quartile and incident fracture rate 
(per 1,000 person-years) was assessed and 
adjusted for age, family history of hip 
fracture, and prevalent fragility fracture. 
Using a risk stratification approach, fracture 
rate (per 1,000 person-years) was 
calculated based on the combination of hip 
BMD (according to quartile distribution) 
and serum level of DKK2 (lowest two 
quartiles vs. highest two quartiles). Fracture 
rate was calculated considering the 
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presence of CRFs (age, age and presence of 
prevalent low-impact fracture, age and 
family history of hip fracture) and serum 
level of DKK2 (lowest two quartiles vs. 
highest two quartiles).  
Finally, facture rate was calculated 
considering the 10-year risk of major 
fracture (<11% vs. ≥11%) without BMD and 
serum level of DKK2 (according to quartile 
distribution). The FRAX score cut-off was 
based on the Portuguese recommendation 
for fracture risk prediction(57). 
Statistical significance was considered as 
p<0.05. All analyses were performed 
using Stata IC, version 12 (StataCorp. 
2011. Stata Statistical Software: Release 
12. College Station, TX, USA: StataCorp 
LP.). 
Ethical approval 
The EpiDoC cohort study was approved by 
the Ethics Committee of NOVA Medical 
School and the Portuguese Data Protection 
Authority (Comissão Nacional de Proteção 
de Dados). Written informed consent in 
accordance with principles established by 
the Declaration of Helsinki was obtained 
from all participants. Further details related 
to ethical issues are described elsewhere(58).  
Results 
Of 3,877 participants evaluated by a 
rheumatologist at baseline, 884 were 
women aged ≥65 years. After applying 
exclusion criteria, 828 women were 
included in this study (Figure 1). During a 
mean follow-up of 2.3±1.0 years, a total of 
62 fragility fractures were sustained in 58 
women. Most incident fragility fractures 
(n=51; 82.3%) were non-hip, non-vertebral 
(i.e., wrist, lower leg, humerus, rib, clavicle, 
and elbow). Incident hip or vertebral 
fractures were reported by 6 (9.7%) and 4 
(6.6%) women, respectively. Senior women 
with incident fragility fractures had 
significantly more prior fractures and had 
more frequently a family history of hip 
fractures. No other CRFs were associated 
with incident fragility fracture (Table 1). 
Table 1. Crude analysis of socio-demographic and economic characteristics, risk factors for 
fractures, and health status of Portuguese women aged ≥65 years with or without incident 
fragility fractures. 
 
All (n=828) 
No incident 
fragility fracture 
(n=669) 
Incident fragility 
fracture (n=58) p-value 
Age (years) 
65–69 270 (32.61%) 232 (34.68%) 17 (29.31%) 0.2770 
70–79 414 (50.00%) 339 (50.67%) 28 (48.28%)  
≥80 144 (17.39%) 98 (14.65%) 13 (22.41%)  
BMI (kg/m2) 
Underweight 7 (0.86%) 5 (0.76%) 0 (0%) 0.8660 
Normal 205 (25.31%) 161 (24.51%) 14 (24.14%)  
Overweight 358 (44.20%) 280 (42.62%) 28 (48.28%)  
Obese 240 (29.63%) 211 (32.12%) 16 (27.59%)  
Family history of hip fracture  
Yes 51 (6.17%) 37 (5.54%) 8 (13.79%) 0.016† 
No 776 (93.83%) 631 (94.46%) 50 (86.21%)  
Current smoking  
Yes 16 (1.93%) 14 (2.10%) 1 (1.72%) 0.849 
No 811 (98.07%) 654 (97.90%) 57 (98.28%)  
High alcohol intake (≥3 units/day)  
Yes 14 (1.69%) 13 (1.95%) 1 (1.72%) 0.906 
No 813 (98.31%) 655 (98.05%) 57 (98.28%)  
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All (n=828) 
No incident 
fragility fracture 
(n=669) 
Incident fragility 
fracture (n=58) p-value 
Physical activity  
Inactive 488 (84.87%) 443 (84.70%) 43 (86.00%) 0.807 
Active 87 (15.13%) 80 (15.30%) 7 (14.00%)  
Number of falls in 
previous 12 months 
1.19±3.41 1.03±2.95 1.34±2.27 0.450 
Use of glucocorticoids  
Yes 30 (3.63%) 23 (3.44%) 4 (6.90%) 0.192 
No 797 (96.37%) 645 (96.56%) 54 (93.10%)  
Rheumatoid arthritis 
Yes 13 (1.57%) 11 (1.65%) 1 (1.72%) 0.965 
No 814 (98.43%) 657 (98.35%) 57 (98.28%)  
Secondary osteoporosis  
Yes 25 (3.02%) 20 (2.99%) 3 (5.17%) 0.370 
No 802 (96.98%) 648 (97.01%) 55 (94.83%)  
Chronic renal insufficiency (mL/min/1.73 m2) 
eGFR <30 16 (2.51%) 13 (2.50%) 2 (4.76%) 0.392 
eGFR ≥30  621 (97.49%) 506 (97.50%) 40 (95.24%)  
Prevalent fragility fracture (self-reported) 
Yes 172 (21.83%) 121 (18.94%) 26 (45.61%) <0.001a 
No 616 (78.17%) 518 (81.06%) 31 (54.39%)  
Prevalent fragility fracture site (self-reported) 
Hip 10 (1.27%) 4 (0.63%) 2 (3.51%) 0.046a 
Vertebral 11 (1.40%) 7 (1.10%) 2 (3.51%) 0.144 
Non-hip/non-vertebral 121 (15.94%) 86 (13.85%) 16 (32.00%) 0.001a 
FRAX score without BMD 
10-year risk of major 
fracture (mean±SD) 
9.62±6.85 9.00±6.04 12.83±10.71 <0.001a 
10-year risk of hip fracture 
(mean±SD) 
4.24±5.20 3.79±4.29 6.64±9.78 <0.001a 
Vertebral BMD (g/cm2) 
Vertebral BMD 
(mean±SD) 
0.99±0.21 1.00±0.21 0.97±0.21 0.471 
Vertebral BMD (T-score)     
Osteoporosis (£-2.5) 69 (25.75%) 55 (23.81%) 6 (35.29%) 0.517 
Osteopenia (>-2.5 and <-
1) 
89 (33.21%) 78 (33.77%) 4 (23.53%)  
Normal (³-1) 110 (41.04%) 98 (42.42%) 7 (41.18%)  
Axial BMD (t-score) 
Osteoporosis (£-2.5) 74 (27.31%) 59 (25.32%) 7 (38.89%) 0.398 
Osteopenia (>-2.5 and <-
1) 
128 (47.23%) 111(47.64%) 6 (33.33%)  
Normal (³-1) 69 (25.46%) 63 (27.04%) 5 (27.78%)  
Hip BMD (g/cm2) 
Hip BMD (mean±SD) 0.78±0.14 0.78±0.14 0.79±0.12 0.865 
Hip BMD (T-score)     
Osteoporosis (£-2.5) 27 (9.93%) 21 (8.97%) 3 (16.67%) 0.464 
Osteopenia (>-2.5 and <-
1) 
139 (51.10%) 119 (50.85%) 7 (38.89%)  
Normal (³-1) 106 (38.97%) 94 (40.17%) 8 (44.44%)  
Vitamin D (mmol/mL) 
Deficiency (<10) 18 (2.96%) 15 (3.02%) 3 (7.50%) 0.341 
Insufficiency (³10 and < 
30) 
212 (34.81%) 175 (35.28%) 13 (32.50%)  
Normal (≥10) 379 (62.23%) 306 (61.69%) 24 (60.00%)  
BTMs 
CTX-I (ng/mL) 0.25±0.16 0.25±0.16 0.27±0.21 0.612 
P1NP (ng/mL) 41.06±20.50 39.75±18.36 41.39±20.06 0.716 
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All (n=828) 
No incident 
fragility fracture 
(n=669) 
Incident fragility 
fracture (n=58) p-value 
Osteocalcin (ng/mL) 3.77±2.46 3.60±2.28 4.05±1.85 0.412 
PTH (ng/mL) 49.38±38.69 47.69±36.45 50.24±46.56 0.681 
Serum levels of Wnt regulators 
DKK2 (ng/mL) 7.79±2.86 7.75±2.75 6.86±2.39 0.144 
sFRP-1 (ng/mL) 2.02±1.37 1.92±1.31 2.56±1.37 0.035 a 
SOST (pmol/L) 31.89±13.96 32.14±13.80 30.91±15.64 0.700 
DKK1 (pmol/L) 132.24±76.48 136.76±76.74 118.16±81.00 0.311 
Sample size is not constant. All: BMI (n=810), family history of hip fracture (n=827), current smoking (n=827), high 
alcohol intake (n=827), physical activity (n=575), number of falls in previous 12 months (n=784), glucocorticoid use 
(n=827), rheumatoid arthritis (n=827), secondary osteoporosis (n=827), chronic renal insufficiency (n=637), prevalent 
fragility fracture (n=788), hip (n=788), vertebral (n=788), non-vertebral/non-hip (n=759), prevalent vertebral fracture 
(n=318), FRAX major (n=820), FRAX hip (n=820), vertebral BMD (n=268), hip BMD (n=271), vitamin D (n=609), CTX-I 
(n=289), P1NP (n=287), osteocalcin (n=291), PTHi (n=592), SOST (n=321), DKK1 (n=290), DKK2 (n=319), sFRP1 (n=321). 
No incident fragility fracture: BMI (n=657), family history of hip fracture (n=668), current smoking (n=668), high 
alcohol intake (n=668), physical activity (n=523), number of falls in previous 12 months (n=634), glucocorticoid use 
(n=668), rheumatoid arthritis (n=668), secondary osteoporosis (n=668), chronic renal insufficiency (n=519), prevalent 
fragility fracture (n=639), hip (n=639), vertebral (n=639), non-vertebral/non-hip (n=621), prevalent vertebral fracture 
(n=276), FRAX major (n=663), FRAX hip (n=663), vertebral BMD (n=231), hip BMD (n=233), vitamin D (n=496), CTX-I 
(n=241), P1NP (n=241), osteocalcin (n=243), PTHi (n=481), SOST (n=277), DKK1 (n=249), DKK2 (n=275), sFRP-1 
(n=276). Incident fragility fracture: physical activity (n=50), number of falls in previous 12 months (n=56), chronic 
renal insufficiency (n=42), prevalent fragility fracture (n=57), hip (n=57), vertebral (n=57), non-vertebral/non-hip 
(n=50), prevalent vertebral fracture (n=21), FRAX major (n=57), FRAX hip (n=57), vertebral BMD (n=17), hip BMD 
(n=18), vitamin D (n=40), CTX-I (n=18), P1NP (n=18), osteocalcin (n=18), PTHi (n=39), SOST (n=20), DKK1 (n=19), DKK2 
(n=21), sFRP1 (n=21). a p<0.05.
Serum levels of sFRP-1, SOST, and DKK1 are 
associated with BMD  
There was no correlation between serum 
levels of DKK2 and BMD (Table 2). Serum 
levels of sFRP-1 and SOST were positively 
correlated with lumbar and hip BMD (Table 
2). When BMD was categorized by T-score, 
the positive correlations for both sFRP-1 
and SOST were lost, except for in the normal 
BMD group. After adjusting for age, BMI, 
family history of hip fracture, physical 
activity, and glucocorticoid use, serum level 
of sFRP-1 was positively correlated with 
vertebral BMD (b=0.040, p<0.001) and hip 
BMD (b=0.011, p=0.001; Table 3). Using the 
same adjustment parameters, SOST levels 
were still positively correlated with 
vertebral BMD (b=0.001, p<0.001) and 
negatively correlated with hip BMD (b=-
0.002, p=0.001; Table 3). 
By contrast, serum levels of DKK1 were 
negatively correlated with hip femoral neck 
BMD. This association remained significant 
even after adjusting for CRFs (b=-0.0004, 
p=0.008; Table 3).  
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Table 2. Correlations between serum levels of DKK2, SOST, DKK1, and sFRP-1, and BMD stratified 
by t-score groups. 
 Vertebral BMD (g/cm2) Hip BMD (g/cm2) 
 Continuous 
(g/cm2) 
Osteoporosis 
(t-score ≤-
2.5) 
Osteopenia 
(t-score >-2.5 
and <-1) 
Normal 
(t-score 
≥-1) 
Continuous 
(g/cm2) 
Osteoporosis 
(t-score ≤-
2.5) 
Osteopenia 
(t-score >-
2.5 and <-1) 
Normal 
(t-score 
≥-1) 
DKK2 
(ng/mL) -0.0537 -0.1415 0.0774 0.0042 -0.0279 0.0081 0.0194 -0.0034 
sFRP-1 
(ng/mL) 0.2603
c 0.0652 0.1864 0.4066c 0.1621a 0.0223 0.1912 0.1172 
SOST 
(pmol/L) 0.2944
c -0.1569 0.0591 0.2099a 0.1917b 0.0244 0.1781 0.0053 
DKK1 
(pmol/L) -0.0162 0.1610 -0.2916
 a -0.0385 -0.1725b -0.1662 -0.2235a -0.2083 
Sample size is not constant. Vertebral BMD: SOST (n=245), DKK1 (n=220), DKK2 (n=243), sFRP-1 (n=244). Hip BMD: 
SOST (n=247), DKK1 (n=218), DKK2 (n=245), sFRP1 (n=246). a p<0.05, b p<0.01, c p<0.001. 
Table 3. Crude and adjusted analysis of associations between serum levels of DKK2, SOST, DKK1, 
and sFRP-1, and BMD. 
 Vertebral BMD (g/cm2) Hip BMD (g/cm2) 
 Crude Adjusted Crude Adjusted 
 β p β p β p β p 
DKK2 (ng/mL) -0.004 0.404 -0.003 0.536 -0.002 0.664 -0.002 0.613 
sFRP-1 (ng/mL) 0.040 <0.001a 0.043 <0.001a 0.016 0.011a 0.016 0.020a 
SOST (pmol/L) 0.005 <0.001a 0.005 <0.001a 0.002 0.002a -0.002 0.001a 
DKK1 (pmol/L) -0.000 0.811 -0.000 0.867 -0.0003 0.011a -0.0004 0.008a 
Sample size is not constant. Crude vertebral BMD: SOST (n=245), DKK1 (n=220), DKK2 (n=243), sFRP1 (n=244). Crude 
hip BMD: SOST (n=247), DKK1 (n=218), DKK2 (n=245), sFRP1 (n=246). Adjusted vertebral BMD: SOST (n=178), DKK1 
(n=163), DKK2 (n=177), sFRP1 (n=176). Adjusted hip BMD: SOST (n=182), DKK1 (n=164), DKK2 (n=181), sFRP1 (n=180). 
Adjusted for age, BMI, family history of hip fracture, physical activity, and glucocorticoid use. a p<0.05.
Serum levels of DKK2 and sFRP-1 are 
independently associated with incident low-
impact fracture 
Low serum level of DKK2 was associated 
with an increased risk of low-impact 
fracture in Cox proportional hazards models 
(Table 4). This association remained 
significant after adjusting for independent 
CRFs for low-impact fracture identified in 
this population: age, family history of hip 
fracture, and prevalent fragility fracture [HR 
(95% CI) per 1 SD increase, 0.61 (0.39; 
0.98)]. The HR also remained significant 
after adjusting for vertebral BMD [HR (95% 
CI) per 1 SD increase, 0.47 (0.27; 0.82)] and 
hip BMD [HR (95% CI) per 1 SD increase, 
0.53 (0.32; 0.88); Table 4]. Women in the 
two highest DKK2 quartiles had a fracture 
incidence rate of 14 per 1,000 person-years, 
whereas women in the two lowest DKK2 
quartiles had a fracture incidence rate of 32 
per 1,000 person-years (Figure 2).  
High serum level of sFRP-1 was associated 
with an increased risk of low-impact 
fracture [HR (95% CI) per 1 SD increase, 1.45 
(1.01; 2.09)]. This association was 
independent of CRFs [HR (95% CI) per 1 SD 
increase, 1.62 (1.09; 2.42)], but dependent 
on BMD (Table 4). Women in the two lowest 
sFRP-1 quartiles had a fracture incidence 
rate of 11 per 1,000 person-years, whereas 
women in the two highest sFRP1 quartiles 
had a fracture incidence rate of 31 per 1,000 
person-years (Figure 2).  
Cox proportional hazards models showed 
no association between serum level of SOST 
or DKK1 and fracture risk in senior women. 
Also, no associations were found between 
BTMs and low-impact fracture incidence 
(Table 4).
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Figure 2. Association between DKK2 and sFRP-1 quartiles with incident fracture rate (per 1,000 
person-years). Women in the two highest DKK2 quartiles had a significantly lower fracture 
incidence than women in two lowest DKK2 quartiles. 
 
Table 4. Crude and adjusted analysis of associations between serum levels of Wnt regulators 
and BTMs and incident fragility fracture. 
Incidence fracture Continuous Per 1 SD increase 
WNT regulators 
DKK2 (ng/mL) HR p HR p 
Crude 0.861 (0.738; 1.006) 0.059 0.655 (0.423; 1.016) 0.059 
CRFs adjusted1 0.842 (0.714; 0.993) 0.041† 0.615 (0.386; 0.979) 0.041a 
CRFs+vertebral BMD adjusted2 0.767 (0.630; 0.933) 0.008† 0.471 (0.271; 0.821) 0.008a 
CRFs+hip BMD adjusted3 0.798 (0.665; 0.958) 0.015† 0.529 (0.316; 0.885) 0.015a 
sFRP-1 (ng/mL) HR p HR p 
Crude 1.318 (1.008; 1.722) 0.043† 1.453 (1.011; 2.087) 0.043a 
CRFs adjusted1 1.431 (1.067; 1.918) 0.017† 1.624 (1.092; 2.416) 0.017a 
CRFs+vertebral BMD adjusted2 1.265 (0.891; 1.796) 0.188 1.375 (0.856; 2.209) 0.188 
CRFs+hip BMD adjusted3 1.329 (0.971; 1.819) 0.075 1.470 (0.961; 2.248) 0.075 
SOST (pmol/L) HR p HR p 
Crude 1.001 (0.970; 1.033) 0.939 1.017 (0.661; 1.564) 0.939 
CRFs adjusted1 1.007 (0.975; 1.039) 0.677 1.097 (0.709; 1.696) 0.677 
CRFs+vertebral BMD adjusted2 0.999 (0.957; 1.043) 0.956 0.983 (0.545; 1.774) 0.956 
CRFs+hip BMD adjusted3 0.989 (0.949; 1.030) 0.578 0.853 (0.488; 1.491) 0.578 
DKK1 (pmol/L) HR p HR p 
Crude 0.998 (0.990; 1.003) 0.512 0.845 (0.511; 1.396) 0.512 
CRFs Adjusted1 0.996 (0.989; 1.004) 0.307 0.743 (0.421; 1.313) 0.307 
CRFs+vertebral BMD adjusted2 0.993 (0.983; 1,003) 0.151 0.588 (0.285; 1.214) 0.151 
CRFs+hip BMD adjusted3 0.991 (0.982; 1.000) 0.078 0.510 (0.241; 1.079) 0.078 
Bone Turnover Markers 
CTX-I (ng/mL) HR p HR p 
Crude 2.076 (0.197; 21.862) 0.543 1.126 (0.768; 1.652) 0.543 
CRFs adjusted1 2.687 (0.241; 29.973) 0.422 1.175 (0.793; 1.740) 0.422 
CRFs+vertebral BMD adjusted2 1.469 (0.001; 3849.7) 0.924 1.065 (0.295; 3.836) 0.924 
CRFs+hip BMD adjusted3 1.024 (0.001; 1544.9) 0.995 1.004 (0.305; 3.306) 0.995 
P1NP (ng/mL) HR p HR p 
Crude 1.005 (0.981; 1.030) 0.679 1.111 (0.679; 1.813) 0.679 
CRFs adjusted1 1.010 (0.985; 1.035) 0.434 1.217 (0.744; 1.992) 0.434 
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Incidence fracture Continuous Per 1 SD increase 
CRFs+vertebral BMD adjusted2 1.032 (0.965; 1.104) 0.361 1.885 (0.484; 7.346) 0.361 
CRFs+hip BMD adjusted3 1.025 (0.966; 1.088) 0.413 1.654 (0.496; 5.521) 0.413 
Osteocalcin (ng/mL) HR p HR p 
Crude 1.075 (0.925; 1.250) 0.346 1.191 (0.828; 1.713) 0.346 
CRFs adjusted1 1.091 (0.936; 1.272) 0.266 1.234 (0.852; 1.787) 0.266 
CRFs+vertebral BMD adjusted2 1.299 (0.963; 1.751) 0.087 1.879 (0.913; 3.868) 0.913 
CRFs+hip BMD adjusted3 1.123 (0.870; 1.450) 0.373 1.324 (0.714; 2.452) 0.373 
1Adjusted for age, family history of hip fracture, and prevalent fragility fracture (self-reported). 2Adjusted for age, 
family history of hip fracture, prevalent fragility fracture (self-reported), and vertebral BMD. 3Adjusted for age, family 
history of hip fracture, prevalent fragility fracture (self-reported), and hip BMD. Sample size is not constant. SOST: 
crude (n=529), adjusted1 (n=496), adjusted2 (n=368), adjusted3 (n=371). DKK1: crude (n=476), adjusted1 (n=443), 
adjusted2 (n=323), adjusted3 (n=320). DKK2: crude (n=527), adjusted1 (n=494), adjusted2 (n=366), adjusted3 (n=369). 
sFRP-1: crude (n=529), adjusted1 (n=496), adjusted2 (n=366), adjusted3 (n=369). CTX-I: crude (n=450), adjusted1 
(n=420), adjusted2 (n=138), adjusted3 (n=138). P1NP: crude (n=451), adjusted1 (n=421), adjusted2 (n=138); adjusted3 
(n=140). Osteocalcin: crude (n=455), adjusted1 (n=425), adjusted2 (n=138), adjusted3 (n=140). a p<0.05. 
 
 
Serum level of DKK2 improves fracture risk 
prediction independently of BMD, CRFs, and 
FRAX score   
Using a risk-stratified approach, the fracture 
incidence rate (per 1,000 person-years) was 
calculated based on the combination of hip 
BMD, CRFs, baseline 10-year risk of major 
fracture using FRAX score (without BMD), 
and serum level of DKK2 (Figure 3). Women 
in the lowest hip BMD quartile and the two 
lowest DKK2 quartiles had the highest 
fracture incidence rate (41 per 1,000 
person-years; Figure 3A). Among women 
with a history of low-impact fracture, 
women in the two lowest DKK2 quartiles 
had a higher fracture rate (96 per 1,000 
person-years) than women in the two 
highest DKK2 quartiles (33 per 1,000 
person-years), although this difference did 
not reach statistical significance, 
presumably due to the low incidence of 
events (p=0.08; Figure 3B). Serum level of 
DKK2 did not discriminate among women 
with a family history of hip fracture (Figure 
3B). 
Women with a 10-year risk of major 
fracture <11% (18 per 1,000 person-years) 
had a lower fracture incidence rate than 
women with a 10-year risk of major fracture 
≥11% [41 per 1,000 person-years, p<0.001; 
HR (95% CI) per 1 SD increase, 2.37 (1.40; 
4.00)]. When we calculated fracture rate, 
based on a combination of FRAX score and 
DKK2 serum level, women in the two lowest 
DKK2 quartiles had the highest fracture 
incidence rate independently of 10-year risk 
of major fracture (Figure 3C). 
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Figure 3. Relationship between DKK2 quartiles and hip BMD terciles (A), CRF (B), and FRAX score 
with incident fracture rate (per 1,000 person-years). Women in the lowest hip BMD tercile and 
the two lowest DKK2 quartiles had the highest fracture incidence rate (A). Among women with 
a history of low-impact fracture, women in the two lowest DKK2 quartiles had a higher fracture 
rate (B). Women in the two lowest DKK2 quartiles had the highest fracture incidence rate 
independently of being under or above the cut-off for 10-year major fracture risk (i.e., 11%) (C). 
 
Discussion 
The present study, conducted in a 
population-based cohort of senior women, 
showed that low serum level of DKK2 
predicted low-impact fractures, 
independently of BMD and CRFs for fracture. 
For every 1 SD decrease in DKK2, fracture 
risk increased by approximately 1.5-fold. 
Serum levels of DKK2 were not associated 
with vertebral or hip BMD. Our results 
suggest a possible interaction among BMD, 
FRAX score without BMD, and serum DKK2 in 
the assessment of fracture risk, which would 
need to be further investigated in a larger 
study with a longer follow-up period.  
DKK2 inhibits Wnt-b-catenin signalling by 
binding to low-density lipoprotein receptor-
related proteins 5 and 6(59) and acts as a fine-
tuning regulator of osteoblast 
differentiation and function(40). DKK2 is 
upregulated in osteoarthritis subchondral 
bone (with local high bone mass), and in 
vitro upregulation of DKK2 in osteoblasts 
increases their ability to form mineralized 
nodules(60). By contrast, DKK2 deficiency in 
vivo leads not only to mineralization 
disturbances and bone fragility but also to a 
moderate reduction in bone mass(40). These 
results are in line with our present findings 
showing that decreased serum level of DKK2 
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was associated with bone fragility fracture 
but not with vertebral and hip BMD. This 
may be due to the fact that osteoblast 
mineralization disturbances, signalled by low 
levels of DKK2, lead to bone 
nanoarchitecture disorganization and 
fragility, independently of bone mass loss(61-
63). 
Overexpression of sFRP-1 in human 
osteoblasts accelerates the rate of cell death 
and, thus, inhibits bone formation(38,64). 
Concordantly, we found that high levels of 
sFRP-1 was associated with incident low-
impact fracture, independent of CRFs for 
fracture. However, this association was not 
independent of BMD. Surprisingly, in our 
study, high serum levels of sFRP-1 and SOST 
were significantly associated with high 
vertebral and hip BMD. Given that sFRP-1 
and SOST inhibit osteoblast proliferation and 
maturation, we would have expected a 
negative correlation with BMD. Other 
studies also found the same paradoxical 
results(36,43,65). Of interest, when we analysed 
the association between serum levels of 
SOST and sFRP-1 and BMD categorized by T-
score, we confirmed the existence of 
correlations in women with normal BMD but 
not with osteopenia or osteoporosis. One 
possible explanation is that, in healthy 
individuals, normal BMD is maintained 
through local downregulation of Wnt 
inhibitors in association with high systemic 
serum levels of SOST and sFRP-1. In 
agreement with this possibility, serum level 
of SOST is higher in men (who have a lower 
global fracture risk) than in women(66). 
However, in pathological situations, as in 
individuals with bone fragility and a high risk 
of fracture, this regulation system is 
disrupted, and serum levels of Wnt 
regulators are associated with osteoblast 
dysfunction, bone fragility, and fracture, as 
our results showed.  
In our study, serum levels of SOST were not 
significantly associated with incident low-
impact fracture. Similarly, the OFELY study 
followed postmenopausal women for 6 
years and reported no association between 
serum level of SOST and incident fracture(42). 
Amrein et al. also found no association 
between SOST serum level and fragility 
fractures in institutionalized elderly 
women(67). By contrast, the Center of 
Excellence for Osteoporosis Research Study 
followed 707 postmenopausal women and 
showed that a high serum SOST level is 
associated with an increased risk of 
fracture(44).  
Although we observed a negative correlation 
between serum levels of DKK1 and BMD, 
similar to what was previously reported(37,68), 
we found no association between DKK1 
serum levels and incident fracture. In a 
cross-sectional study in Sweden, serum 
levels of DKK1 were increased in patients 
with a fresh hip fracture when compared 
with healthy volunteers(69). In contrast, a 
study from Korea did not found an 
association of serum levels of DKK1 and 
prevalent osteoporotic fractures(45).  
We also found no associations between 
serum levels of BTMs (P1NP, CTX-I, and 
osteocalcin) and fragility fractures. Although 
several studies have proposed BTMs as 
fracture risk predictors, their results are not 
conclusive(19,23,70-72). A recent meta-analysis 
reports a modest association between CTX-I 
and fragility fracture, although this 
association is not independent of BMD(23). 
These ambiguous study results probably 
contribute to the low acceptance and utility 
of BTMs in clinical practice and re-enforce 
the need to find alternative markers of 
fragility fracture risk.   
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This study has some limitations. First, 
fragility fractures were self-reported, which 
is less accurate than clinically verified 
vertebral fractures, leading to 
underestimation of their prevalence(73); 
however, the overall performance of self-
reported fragility fractures is respectable(50-
52). Second, the number of incident fractures 
was relatively low because of a short follow-
up duration (2.3±1.0 years). Hence, these 
results must be confirmed in other cohorts 
with more participants and longer follow-up 
periods. Nevertheless, several strengths of 
this study should also be acknowledged. Our 
data came from a large, representative 
sample of the Portuguese adult population 
and participants were examined by 
rheumatologists at baseline. Furthermore, 
different fragility fractures and health-
related measurements were captured, 
providing relevant information about risk 
factors.  
In conclusion, we report that low serum 
levels of DKK2 predicts risk of low-impact 
fractures, independently of BMD and CRFs 
and thus should be explored as a potential 
non-invasive marker of fragility fracture 
risk. High serum level of sFRP-1 were 
significantly associated with fracture, 
although this association was not 
independent of BMD. Both SOST and DKK1 
were associated with BMD but not with 
incident fracture, although the number of 
new fractures recorded may not have 
allowed the detection of these latter 
associations. These results indicate that 
serum DKK2 and sFRP1 may predict low-
impact fracture and suggest that Wnt 
pathway inhibitors should be further 
studied in other populations as potential 
non-invasive markers of fragility fracture 
risk.  
References 
1. Cummings SR, Melton LJ. Epidemiology 
and outcomes of osteoporotic fractures. 
Lancet. May 18 2002;359(9319):1761-7. 
2. Avendano M, Glymour MM, Banks J, 
Mackenbach JP. Health disadvantage in 
US adults aged 50 to 74 years: a 
comparison of the health of rich and 
poor Americans with that of Europeans. 
Am J Public Health. Mar 2009;99(3):540-
8. Epub 2009/01/20. 
3. Johnell O. The socioeconomic burden of 
fractures: today and in the 21st century. 
Am J Med. Aug 18 1997;103(2A):20S-5S; 
discussion 5S-6S. 
4. Looker AC, Orwoll ES, Johnston CC, Jr., 
Lindsay RL, Wahner HW, Dunn WL, et al. 
Prevalence of low femoral bone density 
in older U.S. adults from NHANES III. J 
Bone Miner Res. Nov 1997;12(11):1761-
8. Epub 1998/02/07. 
5. Schuit SC, van der Klift M, Weel AE, de 
Laet CE, Burger H, Seeman E, et al. 
Fracture incidence and association with 
bone mineral density in elderly men and 
women: the Rotterdam Study. Bone. Jan 
2004;34(1):195-202. Epub 2004/01/31. 
6. Kanis JA, Oden A, Johnell O, Johansson H, 
De Laet C, Brown J, et al. The use of 
clinical risk factors enhances the 
performance of BMD in the prediction of 
hip and osteoporotic fractures in men 
and women. Osteoporos Int. Aug 
2007;18(8):1033-46. Epub 2007/02/27. 
7. Hippisley-Cox J, Coupland C. Predicting 
risk of osteoporotic fracture in men and 
women in England and Wales: 
prospective derivation and validation of 
QFractureScores. BMJ. Nov 19 
2009;339:b4229. Epub 2009/11/21. 
8. Nguyen ND, Frost SA, Center JR, Eisman 
JA, Nguyen TV. Development of a 
nomogram for individualizing hip 
fracture risk in men and women. 
SECTION III, PART 1 
 
 
- 173 - 
Osteoporos Int. Aug 2007;18(8):1109-
17. Epub 2007/03/21. 
9. Bolland MJ, Siu AT, Mason BH, Horne 
AM, Ames RW, Grey AB, et al. Evaluation 
of the FRAX and Garvan fracture risk 
calculators in older women. J Bone 
Miner Res. Feb 2011;26(2):420-7. Epub 
2010/08/20. 
10. Kanis JA, Johnell O, Oden A, Johansson H, 
De Laet C, Eisman JA, et al. Smoking and 
fracture risk: a meta-analysis. 
Osteoporos Int. Feb 2005;16(2):155-62. 
Epub 2004/06/04. 
11. Kanis JA, Johnell O, De Laet C, Johansson 
H, Oden A, Delmas P, et al. A meta-
analysis of previous fracture and 
subsequent fracture risk. Bone. Aug 
2004;35(2):375-82. Epub 2004/07/23. 
12. Kanis JA, Johansson H, Oden A, Johnell O, 
de Laet C, Melton IL, et al. A meta-
analysis of prior corticosteroid use and 
fracture risk. J Bone Miner Res. Jun 
2004;19(6):893-9. Epub 2004/05/06. 
13. Kanis JA, Johansson H, Oden A, Johnell O, 
De Laet C, Eisman JA, et al. A family 
history of fracture and fracture risk: a 
meta-analysis. Bone. Nov 
2004;35(5):1029-37. Epub 2004/11/16. 
14. Kanis JA, Johansson H, Johnell O, Oden A, 
De Laet C, Eisman JA, et al. Alcohol intake 
as a risk factor for fracture. Osteoporos 
Int. Jul 2005;16(7):737-42. Epub 
2004/09/30. 
15. Rubin KH, Friis-Holmberg T, Hermann 
AP, Abrahamsen B, Brixen K. Risk 
assessment tools to identify women with 
increased risk of osteoporotic fracture: 
complexity or simplicity? A systematic 
review. J Bone Miner Res. Aug 
2013;28(8):1701-17. Epub 2013/04/18. 
16. Marques A, Ferreira RJ, Santos E, Loza E, 
Carmona L, da Silva JA. The accuracy of 
osteoporotic fracture risk prediction 
tools: a systematic review and meta-
analysis. Ann Rheum Dis. Nov 
2015;74(11):1958-67. Epub 2015/08/08. 
17. Shepstone L, Lenaghan E, Cooper C, 
Clarke S, Fong-Soe-Khioe R, Fordham R, 
et al. Screening in the community to 
reduce fractures in older women 
(SCOOP): a randomised controlled trial. 
Lancet. Feb 24 2018;391(10122):741-7. 
Epub 2017/12/20. 
18. Naylor K, Eastell R. Bone turnover 
markers: use in osteoporosis. Nat Rev 
Rheumatol. Jun 5 2012;8(7):379-89. 
Epub 2012/06/06. 
19. Garnero P, Hausherr E, Chapuy MC, 
Marcelli C, Grandjean H, Muller C, et al. 
Markers of bone resorption predict hip 
fracture in elderly women: the EPIDOS 
Prospective Study. J Bone Miner Res. Oct 
1996;11(10):1531-8. Epub 1996/10/01. 
20. Garnero P, Sornay-Rendu E, Claustrat B, 
Delmas PD. Biochemical markers of bone 
turnover, endogenous hormones and 
the risk of fractures in postmenopausal 
women: the OFELY study. J Bone Miner 
Res. Aug 2000;15(8):1526-36. Epub 
2000/08/10. 
21. Ivaska KK, Gerdhem P, Vaananen HK, 
Akesson K, Obrant KJ. Bone turnover 
markers and prediction of fracture: a 
prospective follow-up study of 1040 
elderly women for a mean of 9 years. J 
Bone Miner Res. Feb 2010;25(2):393-
403. Epub 2009/12/08. 
22. Vasikaran S, Eastell R, Bruyere O, Foldes 
AJ, Garnero P, Griesmacher A, et al. 
Markers of bone turnover for the 
prediction of fracture risk and 
monitoring of osteoporosis treatment: a 
need for international reference 
standards. Osteoporos Int. Feb 
2011;22(2):391-420. Epub 2010/12/25. 
23. Johansson H, Oden A, Kanis JA, 
McCloskey EV, Morris HA, Cooper C, et 
al. A meta-analysis of reference markers 
CHAPTER IV 
 
 
- 174 - 
of bone turnover for prediction of 
fracture. Calcif Tissue Int. May 
2014;94(5):560-7. Epub 2014/03/05. 
24. Hlaing TT, Compston JE. Biochemical 
markers of bone turnover - uses and 
limitations. Ann Clin Biochem. Mar 
2014;51(Pt 2):189-202. Epub 
2014/01/09. 
25. Boyden LM, Mao J, Belsky J, Mitzner L, 
Farhi A, Mitnick MA, et al. High bone 
density due to a mutation in LDL-
receptor-related protein 5. N Engl J Med. 
May 16 2002;346(20):1513-21. Epub 
2002/05/17. 
26. Gong Y, Slee RB, Fukai N, Rawadi G, 
Roman-Roman S, Reginato AM, et al. LDL 
receptor-related protein 5 (LRP5) affects 
bone accrual and eye development. Cell. 
Nov 16 2001;107(4):513-23. Epub 
2001/11/24. 
27. Little RD, Carulli JP, Del Mastro RG, 
Dupuis J, Osborne M, Folz C, et al. A 
mutation in the LDL receptor-related 
protein 5 gene results in the autosomal 
dominant high-bone-mass trait. Am J 
Hum Genet. Jan 2002;70(1):11-9. Epub 
2001/12/13. 
28. Balemans W, Patel N, Ebeling M, Van Hul 
E, Wuyts W, Lacza C, et al. Identification 
of a 52 kb deletion downstream of the 
SOST gene in patients with van Buchem 
disease. J Med Genet. Feb 
2002;39(2):91-7. Epub 2002/02/12. 
29. Brunkow ME, Gardner JC, Van Ness J, 
Paeper BW, Kovacevich BR, Proll S, et al. 
Bone dysplasia sclerosteosis results from 
loss of the SOST gene product, a novel 
cystine knot-containing protein. Am J 
Hum Genet. Mar 2001;68(3):577-89. 
Epub 2001/02/17. 
30. Mani A, Radhakrishnan J, Wang H, Mani 
A, Mani MA, Nelson-Williams C, et al. 
LRP6 mutation in a family with early 
coronary disease and metabolic risk 
factors. Science. Mar 2 
2007;315(5816):1278-82. Epub 
2007/03/03. 
31. Wergedal JE, Veskovic K, Hellan M, 
Nyght C, Balemans W, Libanati C, et al. 
Patients with Van Buchem disease, an 
osteosclerotic genetic disease, have 
elevated bone formation markers, 
higher bone density, and greater derived 
polar moment of inertia than normal. J 
Clin Endocrinol Metab. Dec 
2003;88(12):5778-83. Epub 2003/12/13. 
32. Monroe DG, McGee-Lawrence ME, 
Oursler MJ, Westendorf JJ. Update on 
Wnt signaling in bone cell biology and 
bone disease. Gene. Jan 15 
2012;492(1):1-18. Epub 2011/11/15. 
33. Saag KG, Petersen J, Brandi ML, Karaplis 
AC, Lorentzon M, Thomas T, et al. 
Romosozumab or Alendronate for 
Fracture Prevention in Women with 
Osteoporosis. N Engl J Med. Oct 12 
2017;377(15):1417-27. Epub 
2017/09/12. 
34. Cosman F, Crittenden DB, Adachi JD, 
Binkley N, Czerwinski E, Ferrari S, et al. 
Romosozumab Treatment in 
Postmenopausal Women with 
Osteoporosis. N Engl J Med. Oct 20 
2016;375(16):1532-43. Epub 
2016/11/01. 
35. Diarra D, Stolina M, Polzer K, Zwerina J, 
Ominsky MS, Dwyer D, et al. Dickkopf-1 
is a master regulator of joint remodeling. 
Nat Med. Feb 2007;13(2):156-63. Epub 
2007/01/24. 
36. Modder UI, Hoey KA, Amin S, McCready 
LK, Achenbach SJ, Riggs BL, et al. Relation 
of age, gender, and bone mass to 
circulating sclerostin levels in women 
and men. J Bone Miner Res. Feb 
2011;26(2):373-9. Epub 2010/08/20. 
37. Butler JS, Murray DW, Hurson CJ, O'Brien 
J, Doran PP, O'Byrne JM. The role of Dkk1 
SECTION III, PART 1 
 
 
- 175 - 
in bone mass regulation: correlating 
serum Dkk1 expression with bone 
mineral density. J Orthop Res. Mar 
2011;29(3):414-8. Epub 2010/10/13. 
38. Yao W, Cheng Z, Shahnazari M, Dai W, 
Johnson ML, Lane NE. Overexpression of 
secreted frizzled-related protein 1 
inhibits bone formation and attenuates 
parathyroid hormone bone anabolic 
effects. J Bone Miner Res. Feb 
2010;25(2):190-9. Epub 2009/07/15. 
39. Mao B, Wu W, Davidson G, Marhold J, Li 
M, Mechler BM, et al. Kremen proteins 
are Dickkopf receptors that regulate 
Wnt/beta-catenin signalling. Nature. Jun 
6 2002;417(6889):664-7. Epub 
2002/06/07. 
40. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang 
Y, et al. Dkk2 has a role in terminal 
osteoblast differentiation and 
mineralized matrix formation. Nat 
Genet. Sep 2005;37(9):945-52. Epub 
2005/08/02. 
41. Li L, Mao J, Sun L, Liu W, Wu D. Second 
cysteine-rich domain of Dickkopf-2 
activates canonical Wnt signaling 
pathway via LRP-6 independently of 
dishevelled. J Biol Chem. Feb 22 
2002;277(8):5977-81. Epub 2001/12/14. 
42. Garnero P, Sornay-Rendu E, Munoz F, 
Borel O, Chapurlat RD. Association of 
serum sclerostin with bone mineral 
density, bone turnover, steroid and 
parathyroid hormones, and fracture risk 
in postmenopausal women: the OFELY 
study. Osteoporos Int. Feb 
2013;24(2):489-94. Epub 2012/04/25. 
43. Arasu A, Cawthon PM, Lui LY, Do TP, 
Arora PS, Cauley JA, et al. Serum 
sclerostin and risk of hip fracture in older 
Caucasian women. J Clin Endocrinol 
Metab. Jun 2012;97(6):2027-32. Epub 
2012/04/03. 
44. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-
Senani NS, Qari MH, Mousa SA. High 
serum sclerostin predicts the occurrence 
of osteoporotic fractures in 
postmenopausal women: the Center of 
Excellence for Osteoporosis Research 
Study. J Bone Miner Res. Dec 
2012;27(12):2592-602. Epub 
2012/07/28. 
45. Lim Y, Kim CH, Lee SY, Kim H, Ahn SH, Lee 
SH, et al. Decreased Plasma Levels of 
Sclerostin But Not Dickkopf-1 are 
Associated with an Increased Prevalence 
of Osteoporotic Fracture and Lower 
Bone Mineral Density in 
Postmenopausal Korean Women. Calcif 
Tissue Int. Oct 2016;99(4):350-9. Epub 
2016/06/13. 
46. Rossini M, Viapiana O, Idolazzi L, 
Ghellere F, Fracassi E, Troplini S, et al. 
Higher Level of Dickkopf-1 is Associated 
with Low Bone Mineral Density and 
Higher Prevalence of Vertebral Fractures 
in Patients with Ankylosing Spondylitis. 
Calcif Tissue Int. May 2016;98(5):438-45. 
Epub 2015/12/10. 
47. Rodrigues AM, Eusebio M, Santos MJ, 
Gouveia N, Tavares V, Coelho PS, et al. 
The burden and undertreatment of 
fragility fractures among senior women. 
Arch Osteoporos. Mar 7 2018;13(1):22. 
Epub 2018/03/09. 
48. WHO. Guidelines for preclinical 
evaluation and clinical trials in 
osteoporosis. Geneva. 1998. 
49. Melton LJ, 3rd, Thamer M, Ray NF, Chan 
JK, Chesnut CH, 3rd, Einhorn TA, et al. 
Fractures attributable to osteoporosis: 
report from the National Osteoporosis 
Foundation. J Bone Miner Res. Jan 
1997;12(1):16-23. 
50. Chen Z, Kooperberg C, Pettinger MB, 
Bassford T, Cauley JA, LaCroix AZ, et al. 
Validity of self-report for fractures 
CHAPTER IV 
 
 
- 176 - 
among a multiethnic cohort of 
postmenopausal women: results from 
the Women's Health Initiative 
observational study and clinical trials. 
Menopause. May-Jun 2004;11(3):264-
74. 
51. Ismail AA, O'Neill TW, Cockerill W, Finn 
JD, Cannata JB, Hoszowski K, et al. 
Validity of self-report of fractures: 
results from a prospective study in men 
and women across Europe. EPOS Study 
Group. European Prospective 
Osteoporosis Study Group. Osteoporos 
Int. 2000;11(3):248-54. 
52. Honkanen K, Honkanen R, Heikkinen L, 
Kroger H, Saarikoski S. Validity of self-
reports of fractures in perimenopausal 
women. Am J Epidemiol. Sep 01 
1999;150(5):511-6. 
53. Kanis JA, Johnell O, Oden A, Johansson H, 
McCloskey E. FRAX and the assessment 
of fracture probability in men and 
women from the UK. Osteoporos Int. Apr 
2008;19(4):385-97. Epub 2008/02/23. 
54. Pais-Ribeiro J, Silva I, Ferreira T, Martins 
A, Meneses R, Baltar M. Validation study 
of a Portuguese version of the Hospital 
Anxiety and Depression Scale. Psychol 
Health Med. Mar 2007;12(2):225-35; 
quiz 35-7. 
55. Fonseca JE. Biobanco-IMM, Lisbon 
Academic Medical Centre: a case study. 
Acta Med Port. Jul-Aug 2013;26(4):312-
4. Epub 2013/09/11. 
56. Levey AS, Stevens LA, Schmid CH, Zhang 
YL, Castro AF, 3rd, Feldman HI, et al. A 
new equation to estimate glomerular 
filtration rate. Ann Intern Med. May 05 
2009;150(9):604-12. 
57. Rodrigues AM, Canhao H, Marques A, 
Ambrosio C, Borges J, Coelho P, et al. 
Portuguese recommendations for the 
prevention, diagnosis and management 
of primary osteoporosis - 2018 update. 
Acta Reumatol Port. Jan-Mar 
2018;43(1):10-31. Epub 2018/03/31. 
58. Gouveia N, Rodrigues AM, Ramiro S, 
Machado P, da Costa LP, Mourao AF, et 
al. EpiReumaPt: how to perform a 
national population based study - a 
practical guide. Acta Reumatol Port. Apr-
Jun 2015;40(2):128-36. 
59. Bao J, Zheng JJ, Wu D. The structural 
basis of DKK-mediated inhibition of 
Wnt/LRP signaling. Sci Signal. May 15 
2012;5(224):pe22. Epub 2012/05/17. 
60. Chan TF, Couchourel D, Abed E, 
Delalandre A, Duval N, Lajeunesse D. 
Elevated Dickkopf-2 levels contribute to 
the abnormal phenotype of human 
osteoarthritic osteoblasts. J Bone Miner 
Res. Jul 2011;26(7):1399-410. Epub 
2011/02/12. 
61. Rodrigues AM, Caetano-Lopes J, Vale AC, 
Vidal B, Lopes A, Aleixo I, et al. Low 
osteocalcin/collagen type I bone gene 
expression ratio is associated with hip 
fragility fractures. Bone. Dec 
2012;51(6):981-9. Epub 2012/09/15. 
62. Boivin G, Bala Y, Doublier A, Farlay D, 
Ste-Marie LG, Meunier PJ, et al. The role 
of mineralization and organic matrix in 
the microhardness of bone tissue from 
controls and osteoporotic patients. 
Bone. Sep 2008;43(3):532-8. Epub 
2008/07/05. 
63. Roschger P, Paschalis EP, Fratzl P, 
Klaushofer K. Bone mineralization 
density distribution in health and 
disease. Bone. Mar 2008;42(3):456-66. 
Epub 2007/12/22. 
64. Bodine PV, Billiard J, Moran RA, Ponce-
de-Leon H, McLarney S, Mangine A, et al. 
The Wnt antagonist secreted frizzled-
related protein-1 controls osteoblast 
and osteocyte apoptosis. J Cell Biochem. 
Dec 15 2005;96(6):1212-30. Epub 
2005/09/09. 
SECTION III, PART 1 
 
 
- 177 - 
65. Polyzos SA, Anastasilakis AD, 
Bratengeier C, Woloszczuk W, 
Papatheodorou A, Terpos E. Serum 
sclerostin levels positively correlate with 
lumbar spinal bone mineral density in 
postmenopausal women--the six-month 
effect of risedronate and teriparatide. 
Osteoporos Int. Mar 2012;23(3):1171-6. 
Epub 2011/02/10. 
66. Durosier C, van Lierop A, Ferrari S, 
Chevalley T, Papapoulos S, Rizzoli R. 
Association of circulating sclerostin with 
bone mineral mass, microstructure, and 
turnover biochemical markers in healthy 
elderly men and women. J Clin 
Endocrinol Metab. Sep 2013;98(9):3873-
83. Epub 2013/07/19. 
67. Amrein K, Dobnig H, Wagner D, 
Piswanger-Solkner C, Pieber TR, Pilz S, et 
al. Sclerostin in institutionalized elderly 
women: associations with quantitative 
bone ultrasound, bone turnover, 
fractures, and mortality. J Am Geriatr 
Soc. Jun 2014;62(6):1023-9. Epub 
2014/05/02. 
68. Anastasilakis AD, Polyzos SA, Avramidis 
A, Toulis KA, Papatheodorou A, Terpos E. 
The effect of teriparatide on serum 
Dickkopf-1 levels in postmenopausal 
women with established osteoporosis. 
Clin Endocrinol (Oxf). Jun 
2010;72(6):752-7. Epub 2009/10/17. 
69. Wanby P, Nobin R, Von SP, Brudin L, 
Carlsson M. Serum levels of the bone 
turnover markers dickkopf-1, sclerostin, 
osteoprotegerin, osteopontin, 
osteocalcin and 25-hydroxyvitamin D in 
Swedish geriatric patients aged 75 years 
or older with a fresh hip fracture and in 
healthy controls. J Endocrinol Invest. Aug 
2016;39(8):855-63. Epub 2016/02/07. 
70. Johnell O, Oden A, De Laet C, Garnero P, 
Delmas PD, Kanis JA. Biochemical indices 
of bone turnover and the assessment of 
fracture probability. Osteoporos Int. Jul 
2002;13(7):523-6. Epub 2002/07/12. 
71. Chubb SA, Byrnes E, Manning L, Beilby 
JP, Ebeling PR, Vasikaran SD, et al. 
Reference intervals for bone turnover 
markers and their association with 
incident hip fractures in older men: the 
Health in Men study. J Clin Endocrinol 
Metab. Jan 2015;100(1):90-9. Epub 
2014/10/17. 
72. Shigdel R, Osima M, Ahmed LA, 
Joakimsen RM, Eriksen EF, Zebaze R, et 
al. Bone turnover markers are associated 
with higher cortical porosity, thinner 
cortices, and larger size of the proximal 
femur and non-vertebral fractures. 
Bone. Dec 2015;81:1-6. Epub 
2015/06/27. 
73. Ivers RQ, Cumming RG, Mitchell P, 
Peduto AJ. The accuracy of self-reported 
fractures in older people. J Clin 
Epidemiol. May 2002;55(5):452-7. 
 
 
 
 
 
 
 

  
 
- 179 - 
 
 
 
 
 
SECTION IV 
STRATEGIES TO REDUCE NEW FRAGILITY FRACTURES IN PORTUGUESE 
POPULATION 
 
PART 1 – MARQUES A, RODRIGUES AM, ROMEU JC, ET AL. 2016. MULTIDISCIPLINARY PORTUGUESE 
RECOMMENDATIONS ON DXA REQUEST AND INDICATION TO TREAT IN THE PREVENTION OF FRAGILITY 
FRACTURES. ACTA REUMATOL PORT. 41: 305-321. 
PART 2 – RODRIGUES AM, CANHÃO H, MARQUES A, ET AL. 2018. PORTUGUESE RECOMMENDATIONS 
FOR THE PREVENTION, DIAGNOSIS AND MANAGEMENT OF PRIMARY OSTEOPOROSIS – 2018 UPDATE. ACTA 
REUMATOL PORT. 43:10-31. 
 

  
 
- 181 - 
SECTION IV, PART 1 
 
 
CHAPTER IV 
 
 
- 182 - 
 
SECTION IV, PART 1 
 
 
- 183 - 
 
CHAPTER IV 
 
 
- 184 - 
 
 
SECTION IV, PART 1 
 
 
- 185 - 
 
CHAPTER IV 
 
 
- 186 - 
 
SECTION IV, PART 1 
 
 
- 187 - 
 
 
CHAPTER IV 
 
 
- 188 - 
 
SECTION IV, PART 1 
 
 
- 189 - 
 
 
CHAPTER IV 
 
 
- 190 - 
 
SECTION IV, PART 1 
 
 
- 191 - 
 
CHAPTER IV 
 
 
- 192 - 
 
SECTION IV, PART 1 
 
 
- 193 - 
 
CHAPTER IV 
 
 
- 194 - 
 
 
SECTION IV, PART 1 
 
 
- 195 - 
 
CHAPTER IV 
 
 
- 196 - 
 
SECTION IV, PART 1 
 
 
- 197 - 
 
 
 
 

  
 
- 199 - 
SECTION IV, PART 2 
CHAPTER IV 
 
 
- 200 - 
 
 
SECTION IV, PART 2 
 
 
- 201 - 
 
 
CHAPTER IV 
 
 
- 202 - 
 
 
SECTION IV, PART 2 
 
 
- 203 - 
 
 
CHAPTER IV 
 
 
- 204 - 
 
 
SECTION IV, PART 2 
 
 
- 205 - 
 
 
CHAPTER IV 
 
 
- 206 - 
 
 
SECTION IV, PART 2 
 
 
- 207 - 
 
 
CHAPTER IV 
 
 
- 208 - 
 
 
SECTION IV, PART 2 
 
 
- 209 - 
 
 
CHAPTER IV 
 
 
- 210 - 
 
 
SECTION IV, PART 2 
 
 
- 211 - 
 
 
CHAPTER IV 
 
 
- 212 - 
 
 
SECTION IV, PART 2 
 
 
- 213 - 
 
 
CHAPTER IV 
 
 
- 214 - 
 
 
SECTION IV, PART 2 
 
 
- 215 - 
 
 
CHAPTER IV 
 
 
- 216 - 
 
 
SECTION IV, PART 2 
 
 
- 217 - 
 
 
CHAPTER IV 
 
 
- 218 - 
 
 
SECTION IV, PART 2 
 
 
- 219 - 
 
 
CHAPTER IV 
 
 
- 220 - 
 
  
 
- 221 - 
 
 
 
 
 
 
CHAPTER V 
 
GENERAL DISCUSSION AND CONCLUSIONS 

  
 
- 223 - 
CHAPTER V - GENERAL DISCUSSION AND CONCLUSIONS 
 
The work presented in this thesis focuses on fragility fracture prevention, from 
assessment of an individual patient´s risk to driving changes in health policies. It 
encompasses five major contributions to fragility fracture prevention and management: 
1) we determined the relative importance of osteoporosis and fragility fractures in 
Portugal and identified population strata at highest risk of fractures to establish 
priorities for research and public health actions; 2) we contributed to increasing 
knowledge about the clinical risk factors for fragility fractures associated with bone 
biomechanics; 3) we provided further insight into understanding the mechanisms 
promoting fragility fractures by examining the relationships between osteoblast 
differentiation markers and bone intrinsic mechanical properties; 4) we identified new 
serum markers (among osteoblast differentiation regulators) of bone fragility and 
fractures, which may be used to improve risk stratification; and 5) we contributed to the 
improvement of individual clinical assessment through the development of national 
clinical consensus recommendations regarding fragility fracture risk assessment, 
monitoring, and management.  
The studies presented in this thesis crossed two main areas of clinical research: patient-
oriented mechanistic research and epidemiological research. This interaction between 
laboratory-based research and population-based research enabled us to contribute in a 
robust manner to the scientific understanding of fragility fractures. 
We began by addressing the prevalence and burden of osteoporosis in Portugal (Chapter 
IV, section I, part 1) under the scope of EpiReumaPt study. The results of the study 
showed that 10.2% of Portuguese adults have osteoporosis. In the study, osteoporosis 
was determined clinically by a rheumatologist based on pre-determined criteria. 
Osteoporosis prevalence was higher in women (17%) than in men (2.6%) and increased 
with age. Almost half (40%) of Portuguese adults 75 years of age or older have 
osteoporosis, and a diagnosis of osteoporosis was associated with substantial physical 
functional impairment but not with anxiety or depression symptoms. Contrary to 
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previous studies, we verified that osteoporosis is not less frequent in Portugal than in 
northern European countries (30, 31). Osteoporosis is highly prevalent in Portugal, with 
a prevalence rate similar to that reported in other countries (149-158).  
The second study of this thesis, presented in Chapter IV, Section I, part 2, focused on the 
stratum most vulnerable to osteoporosis and to fragility fractures: senior women 
(women aged ≥65 years old). We evaluated the prevalence of and risk factors for fragility 
fractures, as well as osteoporosis treatment rates, in these women and verified that self-
reported fragility fractures were highly prevalent (20.7%). However, the high prevalence 
of fragility fractures was in stark contrast with the low rate of osteoporosis treatment 
(13.9%). NHNV (lower leg, wrist, humerus, rib, clavicle, and elbow) fractures accounted 
for the majority of fragility fractures, and the clinical risk factors independently 
associated with prevalent fragility fractures were increased age, obesity, and a lower 
distal BMD. The prevalence of fragility fractures among senior women in Portugal was 
similar to that of other Mediterranean countries (2), but slightly lower than the rate in 
other countries of northern Europe (159-161), Australia (162), and the United States of 
America. The finding that NHNV fractures were the most prevalent fracture sites is 
consistent with the results of other studies reporting that NHNV fractures accounted for 
more than two-thirds of all fragility fractures (7, 8, 163). The results of our analysis of 
clinical risk factors for prevalent fragility fractures can be added to those of previous 
studies performed in other populations, especially our findings of age and low distal 
BMD as risk factors (161, 164). The association between obesity and fragility fractures 
(especially NHNV fractures) was reported in other studies (162, 165). It is interesting to 
speculate on the mechanisms by which obesity may confer an increased risk of fracture. 
Recent studies showed that visceral obesity is associated with a low BMD, probably 
because of higher levels of inflammatory cytokines, lower levels of leptin, and higher 
levels of adiponectin (166). Moreover, obese people have a higher risk of falls and 
impaired protective responses (167).  
Worldwide, osteoporosis treatments are not appropriately provided to high-risk 
patients, such as those who have sustained a previous fragility fracture (146, 168). There 
is a large gap between the number of women who are treated and the number of 
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women eligible for treatment (169). The largest treatment gaps were previously 
described in Bulgaria and the Baltic States, where less than 15% of the eligible 
population receives osteoporosis treatment; in Spain, 75% of eligible women do not 
receive osteoporosis treatment (2). Moreover, even in patients who sustain a fragility 
fracture, less than 20% receive treatment in the year following the fracture. Our study 
showed that treatment rates in Portugal are even lower, as only 13.9% of senior women 
who sustained a fragility fracture ever received osteoporosis treatment. Osteoporosis 
treatment was never prescribed in 54.7% of women with a fracture and 23.4% with a 
fracture were offered a prescription but refused treatment. When we calculated the 10-
year risk of a subsequent fragility fracture using the FRAX algorithm without BMD, we 
found that a low proportion of women who were eligible for osteoporosis treatment 
according to Portuguese guidelines (20) were actually receiving this treatment. These 
results highlight the importance of updating osteoporosis treatment guidelines in 
Portugal and ensuring their correct implementation in clinical practice.  
Low treatment rates are not the only reason for the high prevalence of fragility fractures 
in the elderly, and better risk stratification approaches and screening strategies are 
required. Assessment of fracture risk should include the most relevant factors that 
contribute to fragility fractures. The most widely tools for risk assessment are 
measurement of BMD, determination of serum levels of bone turnover markers, and 
the use of algorithms for fracture risk prediction that include weighted clinical risk 
factors for fractures and BMD, such as the FRAX tool (91, 92). The fracture risk prediction 
algorithms, in particular, have improved the identification of individuals with a high risk 
of fractures, but they still fail to identify a substantial number of individuals who will 
have a fragility fracture, especially non-hip fractures (93-95).  
The challenge to better identify seniors at high risk for a fragility fracture led us to search 
for novel noninvasive biomarkers of bone fragility and fractures. To achieve this goal, 
we conducted patient-oriented mechanistic research, looking for associations between 
cellular mechanism dysfunction and bone fragility among the elderly. In the third thesis 
study, presented in Chapter IV, section II, part 1, we compared patients undergoing hip 
replacement surgery because of a fragility fracture with patients undergoing the same 
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surgery because of osteoarthritis. First, we compared bone macrostructural parameters 
between hip fragility fracture and osteoarthritis patients. We demonstrated that when 
adjusted for differences in age, sex, and BMI, the only macrostructural bone 
characteristic still significantly different between the hip fragility fracture and 
osteoarthritis groups was trabecular stiffness. Specifically, it was lower in patients with 
fragility fractures. We also demonstrated that smoking and female sex were 
independently associated with lower stiffness in patients with a hip fragility fracture. 
We did not find significant differences in areal BMD between smokers and non-smokers, 
suggesting that the effects of smoking on trabecular bone’s intrinsic properties are 
independent of areal BMD. Corroborating this, a recent meta-analysis found that a low 
areal BMD accounted for only 23% of the smoking-related risk of hip fracture (116). In 
fact, animal model studies revealed that nicotine reduced bone strength but did not 
affect areal BMD (170). It is interesting to speculate on the mechanisms by which 
smoking is associated with poor bone quality. The changes in bone metabolism induced 
by smoking are not completely clear; however, they may be related to altered 
calciotropic hormone metabolism (171). Smoking may alter the hepatic metabolism of 
vitamin D by influencing 25-hydroxylase in the liver and lowering serum levels of 25-
hydroxyvitamin D, similar to smoking’s ability to enhance hepatic degradation of 
oestrogen (172). Smoking also affects the production and binding of oestradiol (173, 
174). Furthermore, nicotine has direct effects on bone cells: it inhibits osteoblast bone 
formation (175-177) and stimulates osteoclast bone resorption (178).  
This third study was particularly original because it evaluated intrinsic trabecular bone 
hip properties using ex vivo mechanical tests and correlated these results with 
epidemiological and clinical factors in the elderly. Furthermore, it showed that patients 
with hip fractures had significantly lower bone stiffness than those with osteoporosis. 
Disturbances in this intrinsic mechanical property are linked with mineralization 
disturbances (179), and Fratzl-Zelman and colleagues have shown that under-
mineralized bone matrix is associated with fragility fractures (180).  
Considering that osteoblasts are responsible for producing mineralized bone (57, 58), 
we hypothesized that with ageing, bone mineralization is impaired because of 
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osteoblast dysfunction, leading to fragility fractures. Osteoblast differentiation from 
mesenchymal progenitors initially requires the transcription factors RUNX2 and OSX and 
later requires canonical Wnt signalling (181-184). Differentiated osteoblasts synthesize 
COL1a1 and OCL, and the ratio of OCL/COL1a1 expression in bone reflects the 
relationship between osteoblast terminal differentiation and mineralization 
impairment.  
In Chapter IV, Section II, Part 2, we presented the fourth study of this thesis, which was 
conducted using data from patients undergoing hip replacement surgery at Hospital de 
Santa Maria and a large panel of bone factors that are markers of osteoblast 
commitment and differentiation. We evaluated whether osteoblast differentiation 
dysfunction was associated with bone fragility and fractures among elderly patients. We 
have found that OCL relative bone expression and the bone OCL/COL1A1 expression 
ratio (markers of osteoblast terminal differentiation) were significantly lower in patients 
with hip fractures than in those with osteoarthritis. Likewise, in a subset of these 
patients, fewer osteoblasts stained positively for OC in patients with fragility fractures 
than in those with osteoarthritis. We also demonstrated that in patients with hip 
fractures, a low bone OCL/COL1A1 expression ratio was associated with worse 
trabecular mechanical behaviour. Moreover, we found no differences in RUNX2 and OSX 
bone expression between groups, and expression of these transcription factors was not 
associated with bone mechanical behaviour within the groups. These observations 
indicate that commitment to the osteoblast lineage is not compromised in fragility 
fractures, but differentiation of cells to the final stage is impaired, leading to fragility. 
These findings suggest that in patients with hip fractures, imbalance of the OC/COL1A1 
expression ratio reflects disturbances in osteoblast activity, affecting bone metabolism 
and bone matrix/mineral ratio, ultimately leading to bone fragility. In conclusion, this 
work reinforced the importance of osteoblast dysfunction in bone intrinsic properties 
and fractures among elderly.  
In the fifth study of this thesis, presented in Chapter IV, section III, part 1, we 
implemented rigorous research to refine fracture risk assessment in senior women 
through the identification of new serum markers for bone fragility and fractures. The 
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candidate osteoblast-mediated bone formation regulators were the inhibitors of Wnt 
signalling. We decided to use these candidate proteins not only because this pathway is 
a major regulator of osteoblast terminal differentiation but also because prior studies 
identified the importance of Wnt signalling in post-menopausal osteoporosis. It was 
previously shown that serum DKK1 and SOST levels increase with age and are associated 
with loss of bone mass (77-79). Mirza and colleagues found that serum SOST levels were 
significantly higher in post-menopausal women and were inversely associated with the 
free oestrogen index (80). In addition, treatment with either anti-SOST or anti-DKK1 
antibodies in post-menopausal osteoporosis increased bone formation, bone mass, and 
bone strength and were effective in preventing fracture (81, 82, 115). In this study, we 
used a subpopulation of the Nationwide cohort, the EpiDoC cohort, to evaluate whether 
serum levels of Wnt regulators (DKK1, DKK2, SOST, and sFRP-1) were associated with 
bone fragility and fractures and could constitute new markers of fragility fractures. Our 
study showed that low serum levels of DKK2 predicted low-impact fractures 
independently of BMD and clinical risk factors for fractures. For every 1 SD decrease in 
DKK2, fracture risk increased approximately 1.5-fold. Serum levels of DKK2 were not 
associated with vertebral or hip BMD. This may be attributed to the fact that osteoblast 
mineralization disturbances, represented by low levels of DKK2, lead to bone 
nanoarchitecture disorganization and fragility, independent of loss of bone mass (185-
187). We also found that high levels of sFRP-1 were associated with incident low-impact 
fractures, independent of clinical risk factors for fracture. However, this association was 
not independent of BMD. Furthermore, serum levels of SOST were not significantly 
associated with incident low-impact fractures. Similarly, the OFELY study followed post-
menopausal women for 6 years and reported no association between serum levels of 
SOST and incident fractures (188). Amrein et al. also found no association between SOST 
serum levels and fragility fractures in institutionalized elderly women (189). By contrast, 
the Centre of Excellence for Osteoporosis Research Study, which followed 707 post-
menopausal women, reported that a high serum SOST level was associated with an 
increased risk of fractures (190). Although we observed a negative correlation between 
serum levels of DKK1 and BMD, similar to the results of previous reports (79, 191), we 
found no association between DKK1 serum levels and incident fractures. In a cross-
sectional study in Sweden, serum levels of DKK1 were increased in patients with a recent 
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hip fracture when compared with healthy volunteers (192). In contrast, a study from 
Korea found no association between serum DKK1 levels and osteoporotic fractures (193). 
In conclusion, we found that low serum levels of DKK2 predict an increased risk of low-
impact fractures, independent of BMD and clinical risk factors, and should thus be 
explored as a potential noninvasive marker of fragility fracture risk. 
The final work of this thesis, presented in Chapter IV, Section IV, involved the 
development of national clinical consensus recommendations for osteoporosis 
diagnosis and treatment to reduce the incidence of fragility fractures. This work was 
motivated by the observation, which we verified, that among a high-risk population 
(senior women), osteoporosis treatment rates are lower in Portugal than elsewhere in 
Europe. We thereby considered that it was of upmost importance to generate clinical 
consensus recommendations in our country and implement a uniform risk stratification 
approach, a unique screening strategy, and an effective treatment plan for the 
Portuguese adult population with a moderate to high fracture risk.  
Previous recommendations from the Portuguese Society of Rheumatology on 
osteoporosis management were published in 2007 (194). In these recommendations, 
fracture risk assessment was based mostly on BMD in the lumbar spine and hip, as 
determined by DXA. Pharmacological treatment was recommended for patients 
meeting these indications: 1) WHO definition of osteoporosis; 2) osteopenic patients 
with clinical risk factors for fragility fractures; and 3) fragility fracture patients with 
osteopenia and /or other clinical risks.  
Osteoporosis treatment recommendations for post-menopausal women from the 
National Health Directorate, published in 2011 (195), acknowledged that treatment 
decisions should be based on an individual’s absolute risk of fracture. It was recognized 
that an individual’s fracture risk is influenced by several clinical risk factors beyond BMD 
(93, 196, 197). However, because our country did not have valid tools to evaluate 
individual fracture risk, treatment decision recommendations were based on the 
existence of a previous fragility fracture or DXA results plus clinical risk factors (195).  
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The work presented in Chapter IV, Section IV of this thesis, aimed to shift fracture risk 
assessment in Portuguese clinical practice from assessment based mostly on BMD to an 
absolute individual fracture risk estimation. It is well established in the scientific 
literature that screening based on BMD alone fails to predict almost 50% of fragility 
fractures (93, 98). Because of that, several fracture risk prediction algorithms were 
developed, with the FRAX algorithm being the most widely used tool. Absolute fracture 
risk calculation using FRAX (clinical risk factors with or without BMD information) 
increased the prediction of fragility fracture, particularly hip fractures (197). In fact, a 
recent randomized controlled trial, comparing a FRAX-based screening program with 
usual management in women aged 70-85 years in the United Kingdom showed that the 
FRAX screening program effectively reduced the 5-year risk of a hip fracture by 28%, 
although no improvement was found in the prediction of other fragility fractures (94). 
This study, concluded that the FRAX algorithm is a valid tool for fracture risk assessment 
in the community. Regardless, there is still room for improvement in predicting the risk 
of fragility fracture. Future studies should continue to look for new tools that enhance 
fracture risk prediction, such as the serum biomarkers we studied in Chapter IV, Section 
III, part 1.  
The FRAX tool has some caveats (198); however, it is currently the best and most studied 
tool available for fracture risk prediction (25, 199). In fact, a meta-analysis evaluating 
the accuracy of osteoporotic fracture risk prediction tools showed that FRAX has the 
largest number of externally validated and independent studies with satisfactory 
accuracy (area under the curve > 0.709), which was higher than BMD (25). The FRAX tool 
was validated in Portugal by Marques et al. (33), and cost-effectiveness analysis were 
performed to define national treatment thresholds for osteoporosis pharmacological 
treatment (126). To implement this new knowledge in Portugal, clinical consensus 
recommendations regarding fracture risk assessment and treatment plans were 
needed.  
The first consensus recommendations in which the PhD student participated were the 
multidisciplinary recommendations for DXA requests and indications for the treatment 
and prevention of fragility fractures. When generating these recommendations, a panel 
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of 17 persons composed of osteoporosis experts and members of relevant Portuguese 
scientific societies (Rheumatology, Orthopaedics, Endocrinology, Gynaecology, and 
Internal Medicine) defined the questions that needed to be addressed in these 
recommendations; 2 researchers reviewed the literature; the principal investigator 
created draft recommendations; and the 17 experts reformulated and voted on the 
recommendations during two meetings. The consensus recommendations established 
among representatives from different specialities were a very important step in 
improving patient fracture risk stratification. In these recommendations, it was stated 
for the first time in Portugal that “all subjects over age of 50 years should have their 10-
year risk of fracture estimated using FRAX tool with or without DEXA result.” Also, the 
threshold of osteoporosis pharmacological treatment for people with a high risk of 
fractures was based on a cost-effectiveness analysis performed in Portugal.  
In the second study related to consensus recommendations, presented in Chapter IV, 
Section IV, part 2, 55 rheumatologists and rheumatology fellows and one specialized 
rheumatology nurse were involved in the “2018 Update of the Portuguese 
Recommendations for the Prevention, Diagnosis, and Management of Primary 
Osteoporosis.” At the first meeting, relevant questions were defined by the working 
group, and a thorough review of the literature was conducted by research fellows 
(including the PhD student) to address each question. After the literature review, the 
working group prepared proposals for the recommendations, which were presented, 
discussed, and revised in two national meetings and refined through electronic 
consultation. The draft recommendations proposal, which included summaries of the 
supporting evidence, was prepared by the PhD student and principal investigator. The 
draft proposal was reviewed again by the working group. Finally, the document was 
circulated among all Portuguese rheumatologists and rheumatology fellows (N=226), 
who anonymously voted via an online survey on their level of agreement with each 
recommendation. In total, 88 participants (69.8% of the Portuguese rheumatologists 
and rheumatology fellows) voted, and the mean agreement for the recommendations 
was 8.7 on a 10-point numerical rating scale (1 = no agreement, 10 = full agreement). 
Each recommendation was based on the best available evidence and were made as 
“good practice recommendations,” defined as the working group believing the benefits 
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of following the recommendation far outweighed the harms, although the supporting 
evidence was indirect or weak.  
The final recommendations of the Update contain several new and updated 
recommendations. First, a clear statement is made regarding the benefits of assessing 
clinical risk factors for fragility fractures throughout life. The recommendations also 
state (as in the multidisciplinary recommendations) that absolute fracture risk should 
be assessed in all adults after the age of 50 years using the FRAX tool validated for the 
Portuguese population. Pharmacological treatment should be started if an individual has 
a previous fragility fracture or is above the FRAX thresholds previously defined in the 
multidisciplinary recommendations. Furthermore, the final recommendations updated 
the treatment plan, considering efficacy data, costs, benefits, and harms of each drug. 
Overall, the Update provides a useful guide for fracture risk assessment, treatment 
strategies, and patient monitoring, which was generated by the approval of a large 
number of Portuguese rheumatologists and rheumatology fellows.  
 
Conclusions 
In conclusion, this thesis provided rigorous epidemiological data regarding the 
prevalence of osteoporosis and fragility fractures in Portugal. It contributed to refining 
fracture risk assessment through the identification of new serum markers (among 
regulators of osteoblast-mediated bone formation) associated with bone fragility and 
fractures. The identification of these markers arose from mechanistic clinical research 
on bone biomechanics and osteoblast dysfunction in patients with hip fractures. These 
studies showed that fragility fractures are associated with reduced bone stiffness, 
reflecting mineralization disturbances. Reduced osteoblast terminal differentiation is 
also associated with poor bone mechanics and fragility fractures. This thesis also 
describes the formulation of national consensus recommendations regarding fracture 
risk assessment of individuals, as well as osteoporosis clinical management and 
treatment, with the goal of changing clinical practice and reducing the incidence of 
fragility fractures in Portugal. 
GENERAL DISCUSSION AND CONCLUSIONS 
 
 
- 233 - 
 
Future Perspectives and Our Future Research Work 
Many unmet research needs in osteoporosis and fragility fracture field remain to be 
addressed. One item on the agenda for future research is to provide evidence for the 
benefits of a screening strategy based on absolute fracture risk over standard of care, 
particularly to validate the benefits of the treatment thresholds based on cost-
effectiveness analyses over usual care. Fracture risk assessment can be refined, and new 
fragility fracture markers (such as serum biomarkers) that independently increase fracture 
risk can and should be incorporated into the FRAX tool. In our future research, the new 
biomarker for fragility fracture (serum level of DKK2) identified in this PhD thesis can be 
tested over a longer follow-up period in another cohort of Portuguese subjects to 
determine the reproducibility of our findings. If the same results are obtained, it will be 
important to conduct research to test these findings in other countries as well. Other 
interesting future questions are how to incorporate serum biomarkers into an algorithm 
of fracture prediction for testing in long-term observational studies and randomized 
controlled trials and whether we can establish biomarker cut-off values for fragility 
fracture risk prediction. 
Furthermore, fragility fractures must be adequately addressed in older people to reduce 
new fracture events, physical disability, and premature death. We hypothesize that a 
patient-centred solution for the community setting will effectively reduce the incidence 
of fragility fractures among the elderly. We conceptualize healthcare as a continuum, 
provided at the community level, including at home, to promote healthy active ageing 
instead of a reactive system that simply treats acute events and uncontrolled chronic 
diseases. This could be achieved through the development of innovative treatment 
approaches to reduce fracture risk. In our future research, we plan to explore the use 
an interactive online tool composed of a comprehensive multi-module protocol with 
clinical data and a customized intervention strategy. This intervention tool is an online 
streaming platform that creates a visual intervention program protocol of lifestyles and 
treatment adherence. Exercise videos, tips, and simple questionnaires can be uploaded 
into the program. It has a short message service (SMS) notification system and an 
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interactive chat room. All contents can be uploaded by the user and customized 
according to the needs of the individual. This platform will be validated and tested to 
assist seniors living at home who have a high risk of fragility fracture. It will provide 
assistance with falls prevention, long-term self-management, motivation to adhere to 
osteoporosis treatment, and lifestyle improvements. This research concept is based on a 
previous project conducted by our research team that has already shown promising results, 
which involved a television program designed to improve living conditions in the elderly; the 
program is available through all Portuguese television providers (200). Every day, individuals 
were given tasks and tips to improve their physical condition, diet, and lifestyle. All content 
for the proposed projects has already been developed. The new challenge will be to integrate 
the television app with an online interactive platform that will send notifications to individuals 
and allow them to communicate with health professionals, who can answer questions and 
discuss other issues; respond to questionnaires; and record measures they have or have not 
taken. This platform will boost home-based intervention programs in a population at high-risk 
for fragility fracture, in which effective and accessible treatment strategies are clearly needed.  
Finally, we propose to create a national network of coordinator-based systems led by 
rheumatologists for the management of health issues related to fragility fractures. The 
costs and effectiveness in fracture risk reduction of these coordinator-based systems 
should be tested and compared with standard of care (using non-adherent health units 
as comparators). At present, patients with a fragility fracture receive fragmented care 
in Portugal. They typically present with their first fracture to the emergency department 
or an orthopaedic surgeon. Those health care providers focus on repairing the broken 
bones and medically managing acute complications. The identification and management 
of patients with an increased risk of future fragility fracture is another dimension that 
typically occurs in hospital outpatient clinics (such as orthopaedics, rheumatology, or 
endocrinology clinics) or the primary care setting. However, no clear pathway is created 
to ensure that all patients with a fragility fracture are evaluated for future fracture risk, 
osteoporosis, and the need for treatment to prevent future fractures. This proposed 
national network of coordinator-based systems will develop and implement an effective 
referral strategy for patients with a recent fragility fracture (within the past 12 months), 
and a personalized multidisciplinary treatment approach will be created in accordance 
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with Portuguese guidelines to prevent new fragility fractures, disability, and early death. 
This national network coordinator-based integrated system—composed of healthcare 
professionals (using the best evidence in clinical practice), patients, and families—will 
contribute to the attainment of our ultimate goal: preventing fractures in all Portuguese 
seniors.
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